chrysene - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	chrysene	go back to main search page
Accession:	CHEBI:51687	browse the term
Definition:	An ortho-fused polycyclic arene found commonly in the coal tar.
Synonyms:	related_synonym:	1,2,5,6-dibenzonaphthalene; 1,2-Benzophenanthrene; Benz[a]phenanthrene; Chrysen; Formula=C18H12; InChI=1S/C18H12/c1-3-7-15-13(5-1)9-11-18-16-8-4-2-6-14(16)10-12-17(15)18/h1-12H; InChIKey=WDECIBYCCFPHNR-UHFFFAOYSA-N; SMILES=c1ccc2c(c1)ccc1c3ccccc3ccc21; benzo[a]phenanthrene
	alt_id:	CHEBI:33087; CHEBI:34639
	xref:	Beilstein:1909297; CAS:218-01-9; Gmelin:262600; KEGG:C14222
	xref_mesh:	MESH:C031180
	xref:	MetaCyc:CPD-13772; PMID:24128549; PMID:24382467; PMID:24519633; Wikipedia:Chrysene

show annotations for term's descendants Sort by:
Rat (871) Mouse (944) Human (886) Chinchilla (0) Bonobo (0) Dog (0) Squirrel (0) Pig (0) Green Monkey (0) Naked Mole-rat (0) All
Genes (944)

chrysene

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

achalasia, adrenocortical insufficiency, alacrimia

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of AAAS mRNA

NCBI chr15:102,246,682...102,259,194
Ensembl chr15:102,246,687...102,259,206

G

ATP-binding cassette, sub-family B member 1A

increases expression

chrysene results in increased expression of ABCB1 mRNA

NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575

G

ATP-binding cassette, sub-family C member 5

decreases expression
multiple interactions

chrysene results in decreased expression of ABCC5 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ABCC5 mRNA

PMID:26377693 PMID:27858113

NCBI chr16:20,150,053...20,245,178
Ensembl chr16:20,150,053...20,245,144

G

ABI family member 3 binding protein

increases expression
multiple interactions

chrysene results in increased expression of ABI3BP mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ABI3BP mRNA

PMID:26377693 PMID:27858113

NCBI chr16:56,298,179...56,510,498
Ensembl chr16:56,298,241...56,510,498

G

actin-binding LIM protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ABLIM1 mRNA

NCBI chr19:57,021,165...57,303,776
Ensembl chr19:57,021,165...57,303,351

G

BRISC complex subunit

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ABRAXAS2 mRNA

NCBI chr 7:132,460,954...132,486,843
Ensembl chr 7:132,460,954...132,486,840

G

apoptotic chromatin condensation inducer 1

decreases expression
multiple interactions

chrysene results in decreased expression of ACIN1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ACIN1 mRNA

PMID:26377693 PMID:27858113

NCBI chr14:54,879,618...54,924,422
Ensembl chr14:54,879,618...54,924,388

G

acyl-coenzyme A amino acid N-acyltransferase 2

decreases expression

chrysene results in decreased expression of ACNAT2 mRNA

NCBI chr 4:49,374,458...49,408,151
Ensembl chr 4:49,379,840...49,408,151

G

aconitate decarboxylase 1

decreases expression

chrysene results in decreased expression of ACOD1 mRNA

NCBI chr14:103,284,448...103,294,009
Ensembl chr14:103,284,413...103,294,009

G

acyl-CoA thioesterase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ACOT1 mRNA

NCBI chr12:84,056,276...84,064,444
Ensembl chr12:84,056,264...84,065,145

G

acyl-Coenzyme A oxidase-like

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ACOXL mRNA

NCBI chr 2:127,680,717...127,968,172
Ensembl chr 2:127,680,796...127,965,793

G

actin alpha 1, skeletal muscle

increases expression

chrysene results in increased expression of ACTA1 mRNA

NCBI chr 8:124,618,497...124,621,514
Ensembl chr 8:124,618,508...124,621,490

G

actinin alpha 3

increases expression

chrysene results in increased expression of ACTN3 mRNA

NCBI chr19:4,911,244...4,927,937
Ensembl chr19:4,911,244...4,927,937

G

adenosine deaminase

increases expression

chrysene results in increased expression of ADA mRNA

NCBI chr 2:163,565,703...163,592,154
Ensembl chr 2:163,568,504...163,592,159

G

a disintegrin and metallopeptidase domain 33

increases expression

chrysene results in increased expression of ADAM33 mRNA

NCBI chr 2:130,892,739...130,905,734
Ensembl chr 2:130,892,511...130,905,734

G

ADAM-like, decysin 1

increases expression

chrysene results in increased expression of ADAMDEC1 mRNA

NCBI chr14:68,800,829...68,819,535
Ensembl chr14:68,800,829...68,819,544

G

ADAM metallopeptidase with thrombospondin type 1 motif 14

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ADAMTS14 mRNA

NCBI chr10:61,032,886...61,109,447
Ensembl chr10:61,032,891...61,109,217

G

adducin 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ADD3 mRNA

NCBI chr19:53,128,874...53,235,518
Ensembl chr19:53,128,874...53,235,830

G

adhesion G protein-coupled receptor D1

increases expression

chrysene results in increased expression of ADGRD1 mRNA

NCBI chr 5:129,173,741...129,281,663
Ensembl chr 5:129,173,814...129,281,663

G

adhesion G protein-coupled receptor L4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ADGRL4 mRNA

NCBI chr 3:151,143,519...151,250,718
Ensembl chr 3:151,143,524...151,250,723

G

adrenomedullin

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ADM mRNA

NCBI chr 7:110,226,864...110,229,027
Ensembl chr 7:110,226,868...110,229,027

G

apoptosis enhancing nuclease

increases expression
multiple interactions

chrysene results in increased expression of AEN mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of AEN mRNA

PMID:26377693 PMID:27858113

NCBI chr 7:78,545,675...78,560,957
Ensembl chr 7:78,545,602...78,560,957

G

ATP/GTP binding protein-like 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of AGBL2 mRNA

NCBI chr 2:90,613,029...90,664,781
Ensembl chr 2:90,613,071...90,664,781

G

argonaute RISC catalytic subunit 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of AGO2 mRNA

NCBI chr15:72,967,693...73,056,777
Ensembl chr15:72,967,693...73,056,784

G

S-adenosylhomocysteine hydrolase-like 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of AHCYL2 mRNA

NCBI chr 6:29,768,378...29,912,309
Ensembl chr 6:29,768,010...29,912,309

G

AHNAK nucleoprotein

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of AHNAK mRNA

NCBI chr19:8,966,640...9,054,299
Ensembl chr19:8,966,648...9,054,278

G

aryl-hydrocarbon receptor

multiple interactions
affects response to substance
increases activity
affects binding

chrysene binds to and results in increased activity of AHR protein
AHR affects the susceptibility to chrysene
[benz(a)anthracene co-treated with Benzo(a)pyrene co-treated with benzo(j)fluoranthene co-treated with benzo(k)fluoranthene co-treated with chrysene co-treated with fluoranthene co-treated with pyrene] promotes the reaction [indeno(1,2,3-cd)pyrene results in increased activity of AHR protein]; [benz(a)anthracene co-treated with Benzo(a)pyrene co-treated with benzo(j)fluoranthene co-treated with benzo(k)fluoranthene co-treated with chrysene co-treated with indeno(1,2,3-cd)pyrene co-treated with fluoranthene] promotes the reaction [pyrene results in increased activity of AHR protein]; [benz(a)anthracene co-treated with Benzo(a)pyrene co-treated with benzo(j)fluoranthene co-treated with benzo(k)fluoranthene co-treated with chrysene co-treated with indeno(1,2,3-cd)pyrene co-treated with pyrene] promotes the reaction [fluoranthene results in increased activity of AHR protein]; [benz(a)anthracene co-treated with Benzo(a)pyrene co-treated with benzo(j)fluoranthene co-treated with benzo(k)fluoranthene co-treated with indeno(1,2,3-cd)pyrene co-treated with fluoranthene co-treated with pyrene] promotes the reaction [chrysene results in increased activity of AHR protein]; [benz(a)anthracene co-treated with Benzo(a)pyrene co-treated with benzo(j)fluoranthene co-treated with chrysene co-treated with indeno(1,2,3-cd)pyrene co-treated with fluoranthene co-treated with pyrene] promotes the reaction [benzo(k)fluoranthene results in increased activity of AHR protein]; [benz(a)anthracene co-treated with Benzo(a)pyrene co-treated with benzo(k)fluoranthene co-treated with chrysene co-treated with indeno(1,2,3-cd)pyrene co-treated with fluoranthene co-treated with pyrene] promotes the reaction [benzo(j)fluoranthene results in increased activity of AHR protein]; [benz(a)anthracene co-treated with benzo(j)fluoranthene co-treated with benzo(k)fluoranthene co-treated with chrysene co-treated with indeno(1,2,3-cd)pyrene co-treated with fluoranthene co-treated with pyrene] promotes the reaction [Benzo(a)pyrene results in increased activity of AHR protein]; [Benzo(a)pyrene co-treated with benzo(j)fluoranthene co-treated with benzo(k)fluoranthene co-treated with chrysene co-treated with indeno(1,2,3-cd)pyrene co-treated with fluoranthene co-treated with pyrene] promotes the reaction [benz(a)anthracene results in increased activity of AHR protein]; [chrysene binds to and results in increased activity of AHR protein] which results in increased expression of CYP1A1 mRNA; alpha-naphthoflavone inhibits the reaction [[chrysene binds to and results in increased activity of AHR protein] which results in increased expression of CYP1A1 mRNA]; chrysene binds to and results in increased activity of AHR protein; chrysene promotes the reaction [AHR protein results in increased expression of CYP1A1 mRNA]
chrysene binds to AHR protein
chrysene analog results in increased activity of AHR protein; chrysene results in increased activity of AHR protein

PMID:3024361 PMID:8571374 PMID:11525907 PMID:12371477 PMID:12799773 More...

NCBI chr12:35,547,978...35,584,988
Ensembl chr12:35,547,973...35,585,037

G

aryl-hydrocarbon receptor repressor

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of AHRR mRNA

NCBI chr13:74,359,237...74,440,450
Ensembl chr13:74,359,237...74,440,450

G

allograft inflammatory factor 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of AIF1 mRNA

NCBI chr17:35,389,967...35,394,977
Ensembl chr17:35,389,967...35,395,044

G

A kinase anchor protein 12

increases expression

chrysene results in increased expression of AKAP12 mRNA

NCBI chr10:4,216,329...4,309,471
Ensembl chr10:4,216,380...4,309,470

G

A kinase anchor protein 7

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of AKAP7 mRNA

NCBI chr10:25,044,988...25,175,115
Ensembl chr10:25,044,988...25,183,768

G

asparagine-linked glycosylation 14

decreases expression

chrysene results in decreased expression of ALG14 mRNA

NCBI chr 3:121,085,361...121,156,745
Ensembl chr 3:121,085,422...121,156,743

G

alkB homolog 7

decreases expression

chrysene results in decreased expression of ALKBH7 mRNA

NCBI chr17:57,304,339...57,306,340
Ensembl chr17:57,304,339...57,306,322

G

arachidonate lipoxygenase 3

increases expression

chrysene results in increased expression of ALOXE3 mRNA

NCBI chr11:69,016,243...69,039,941
Ensembl chr11:69,016,722...69,039,941

G

ALS2 C-terminal like

increases expression

chrysene results in increased expression of ALS2CL mRNA

NCBI chr 9:110,709,203...110,729,598
Ensembl chr 9:110,708,938...110,729,598

G

angiopoietin-like 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ANGPTL4 mRNA

NCBI chr17:33,993,874...34,000,549
Ensembl chr17:33,992,724...34,000,804

G

ankyrin 3, epithelial

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ANK3 mRNA

NCBI chr10:69,234,608...69,863,266
Ensembl chr10:69,234,603...69,863,268

G

ankyrin repeat domain 12

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ANKRD12 mRNA

NCBI chr17:66,272,698...66,386,242
Ensembl chr17:66,272,693...66,384,084

G

ankyrin repeat domain 26

decreases expression

chrysene results in decreased expression of ANKRD26 mRNA

NCBI chr 6:118,478,261...118,539,244
Ensembl chr 6:118,478,269...118,539,187

G

alanyl aminopeptidase, membrane

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ANPEP mRNA

NCBI chr 7:79,471,551...79,497,958
Ensembl chr 7:79,471,551...79,510,807

G

adaptor protein complex AP-1, sigma 1

increases expression

chrysene results in increased expression of AP1S1 mRNA

NCBI chr 5:137,063,852...137,074,917
Ensembl chr 5:137,063,847...137,074,989

G

apolipoprotein L 11b

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of APOL11B mRNA

NCBI chr15:77,518,151...77,527,486
Ensembl chr15:77,518,146...77,527,486

G

apolipoprotein L 9a

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of APOL9A mRNA

NCBI chr15:77,287,989...77,295,280
Ensembl chr15:77,287,989...77,295,335

G

apolipoprotein L 9b

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of APOL9B mRNA

NCBI chr15:77,613,248...77,620,582
Ensembl chr15:77,613,239...77,620,582

G

androgen receptor

multiple interactions
increases activity
decreases activity

chrysene binds to and results in decreased activity of AR protein; chrysene inhibits the reaction [Metribolone results in increased activity of AR protein]
chrysene results in increased activity of AR protein
chrysene results in decreased activity of AR protein

PMID:10771140 PMID:12799773 PMID:18324785

NCBI chr X:97,192,363...97,366,824
Ensembl chr X:97,192,375...97,366,821

G

amphiregulin

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of AREG mRNA

NCBI chr 5:91,287,458...91,296,291
Ensembl chr 5:91,287,458...91,296,291

G

arginine and glutamate rich 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ARGLU1 mRNA

NCBI chr 8:8,716,307...8,741,818
Ensembl chr 8:8,715,075...8,740,521

G

Rho GTPase activating protein 23

decreases expression

chrysene results in decreased expression of ARHGAP23 mRNA

NCBI chr11:97,295,183...97,393,228
Ensembl chr11:97,306,359...97,393,228

G

Rho guanine nucleotide exchange factor 38

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ARHGEF38 mRNA

NCBI chr 3:132,818,039...132,940,710
Ensembl chr 3:132,818,039...132,940,710

G

Rho guanine nucleotide exchange factor 40

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ARHGEF40 mRNA

NCBI chr14:52,222,158...52,243,704
Ensembl chr14:52,222,176...52,243,708

G

ADP-ribosylation factor-like 3

decreases expression

chrysene results in decreased expression of ARL3 mRNA

NCBI chr19:46,519,548...46,561,621
Ensembl chr19:46,519,535...46,561,637

G

armadillo repeat containing 6

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ARMC6 mRNA

NCBI chr 8:70,672,822...70,687,099
Ensembl chr 8:70,672,822...70,687,116

G

arrestin domain containing 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ARRDC4 mRNA

NCBI chr 7:68,386,742...68,398,986
Ensembl chr 7:68,386,743...68,398,989

G

adipocyte-related X-chromosome expressed sequence 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ARXES2 mRNA

NCBI chr X:134,894,569...134,896,108
Ensembl chr X:134,894,573...134,896,104

G

asialoglycoprotein receptor 2

decreases expression
multiple interactions

chrysene results in decreased expression of ASGR2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ASGR2 mRNA

PMID:26377693 PMID:27858113

NCBI chr11:69,983,470...69,997,013
Ensembl chr11:69,983,470...69,997,013

G

aspartate-beta-hydroxylase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ASPH mRNA

NCBI chr 4:9,449,085...9,669,344
Ensembl chr 4:9,448,069...9,669,344

G

aspartic peptidase, retroviral-like 1

increases expression

chrysene results in increased expression of ASPRV1 mRNA

NCBI chr 6:86,605,216...86,606,692
Ensembl chr 6:86,605,146...86,606,692

G

activating transcription factor 4

increases expression

chrysene results in increased expression of ATF4 mRNA

NCBI chr15:80,139,385...80,141,746
Ensembl chr15:80,139,385...80,141,742

G

autophagy related 4C, cysteine peptidase

increases expression

chrysene results in increased expression of ATG4C mRNA

NCBI chr 4:99,077,181...99,185,495
Ensembl chr 4:99,082,171...99,148,024

G

ATPase type 13A3

decreases expression
multiple interactions

chrysene results in decreased expression of ATP13A3 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ATP13A3 mRNA

PMID:26377693 PMID:27858113

NCBI chr16:30,131,241...30,207,674
Ensembl chr16:30,131,241...30,224,793

G

ATPase, Ca++ transporting, cardiac muscle, slow twitch 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ATP2A2 mRNA

NCBI chr 5:122,591,576...122,640,288
Ensembl chr 5:122,591,576...122,640,288

G

ATP synthase membrane subunit g

decreases expression

chrysene results in decreased expression of ATP5MG mRNA

NCBI chr 9:44,824,546...44,832,470
Ensembl chr 9:44,823,855...44,832,040

G

ATPase, H+ transporting, lysosomal V0 subunit A1

increases expression

chrysene results in increased expression of ATP6V0A1 mRNA

NCBI chr11:100,899,262...100,954,545
Ensembl chr11:100,900,278...100,954,545

G

ATPase, H+ transporting, lysosomal V0 subunit A4

increases expression

chrysene results in increased expression of ATP6V0A4 mRNA

NCBI chr 6:38,025,418...38,101,521
Ensembl chr 6:38,025,418...38,101,521

G

ATPase, H+ transporting, lysosomal V0 subunit E

decreases expression

chrysene results in decreased expression of ATP6V0E mRNA

NCBI chr17:26,895,370...26,918,621
Ensembl chr17:26,882,205...26,918,621

G

ataxin 3

increases expression

chrysene results in increased expression of ATXN3 mRNA

NCBI chr12:101,885,160...101,928,139
Ensembl chr12:101,885,160...101,924,505

G

UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of B4GALT1 mRNA

NCBI chr 4:40,804,602...40,855,711
Ensembl chr 4:40,804,602...40,854,005

G

basic leucine zipper transcription factor, ATF-like

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of BATF mRNA

NCBI chr12:85,733,494...85,755,861
Ensembl chr12:85,733,443...85,755,861

G

BCL2-associated X protein

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of BAX mRNA

NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322

G

butyrylcholinesterase

increases expression

chrysene results in increased expression of BCHE mRNA

NCBI chr 3:73,543,138...73,615,767
Ensembl chr 3:73,543,141...73,615,748

G

branched chain ketoacid dehydrogenase E1, beta polypeptide

decreases expression

chrysene results in decreased expression of BCKDHB mRNA

NCBI chr 9:83,807,190...84,006,293
Ensembl chr 9:83,807,198...84,006,293

G

BCL11 transcription factor A

increases expression

chrysene results in increased expression of BCL11A mRNA

NCBI chr11:24,026,498...24,123,558
Ensembl chr11:24,028,056...24,124,123

G

B cell leukemia/lymphoma 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of BCL3 mRNA

NCBI chr 7:19,542,387...19,556,691
Ensembl chr 7:19,542,387...19,556,695

G

B cell CLL/lymphoma 6, member B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of BCL6B mRNA

NCBI chr11:70,114,953...70,120,624
Ensembl chr11:70,114,954...70,120,624

G

B cell CLL/lymphoma 7B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of BCL7B mRNA

NCBI chr 5:135,197,226...135,210,706
Ensembl chr 5:135,197,137...135,210,709

G

BCL2-associated transcription factor 1

increases expression

chrysene results in increased expression of BCLAF1 mRNA

NCBI chr10:20,187,897...20,218,390
Ensembl chr10:20,188,215...20,220,359

G

bone gamma-carboxyglutamate protein 3

increases expression

chrysene results in increased expression of BGLAP3 mRNA

NCBI chr 3:88,275,923...88,280,048
Ensembl chr 3:88,275,923...88,280,050

G

basic helix-loop-helix family, member e40

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of BHLHE40 mRNA

NCBI chr 6:108,637,590...108,643,886
Ensembl chr 6:108,637,590...108,643,886

G

baculoviral IAP repeat-containing 5

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of BIRC5 mRNA

NCBI chr11:117,740,063...117,746,569
Ensembl chr11:117,740,077...117,746,569

G

biogenesis of lysosomal organelles complex-1, subunit 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of BLOC1S2 mRNA

NCBI chr19:44,127,685...44,134,909
Ensembl chr19:44,127,685...44,134,885

G

basic helix-loop-helix ARNT like 1

decreases expression
multiple interactions

chrysene results in decreased expression of BMAL1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of BMAL1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 7:112,777,820...112,913,333
Ensembl chr 7:112,806,672...112,913,333

G

bone morphogenetic protein receptor type 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of BMPR2 mRNA

NCBI chr 1:59,802,721...59,917,240
Ensembl chr 1:59,802,559...59,918,173

G

bromodomain containing 7

increases expression

chrysene results in increased expression of BRD7 mRNA

NCBI chr 8:89,056,522...89,089,249
Ensembl chr 8:89,057,667...89,088,822

G

BSCL2 lipid droplet biogenesis associated, seipin

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of BSCL2 mRNA

NCBI chr19:8,814,831...8,826,047
Ensembl chr19:8,814,831...8,826,047

G

B and T lymphocyte associated

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of BTLA mRNA

NCBI chr16:45,043,121...45,073,258
Ensembl chr16:45,044,678...45,078,033

G

C2 calcium-dependent domain containing 3

decreases expression
multiple interactions

chrysene results in decreased expression of C2CD3 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of C2CD3 mRNA

PMID:26377693 PMID:27858113

NCBI chr 7:100,021,440...100,119,366
Ensembl chr 7:100,021,440...100,119,359

G

complement component 5a receptor 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of C5AR2 mRNA

NCBI chr 7:15,968,512...15,978,079
Ensembl chr 7:15,968,510...15,978,079

G

complement component 7

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of C7 mRNA

NCBI chr15:5,017,232...5,093,230
Ensembl chr15:5,018,244...5,093,222

G

calcium binding protein 5

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CABP5 mRNA

NCBI chr 7:13,119,885...13,142,812
Ensembl chr 7:13,132,057...13,142,812

G

calcium channel, voltage-dependent, gamma subunit 1

increases expression

chrysene results in increased expression of CACNG1 mRNA

NCBI chr11:107,594,044...107,607,302
Ensembl chr11:107,594,044...107,607,348

G

calmodulin 4

increases expression

chrysene results in increased expression of CALM4 mRNA

NCBI chr13:3,887,757...3,888,671
Ensembl chr13:3,887,757...3,888,673

G

calpain 3

increases expression

chrysene results in increased expression of CAPN3 mRNA

NCBI chr 2:120,294,074...120,335,400
Ensembl chr 2:120,294,053...120,335,399

G

capping actin protein of muscle Z-line subunit alpha 2

decreases expression

chrysene results in decreased expression of CAPZA2 mRNA

NCBI chr 6:17,637,009...17,666,971
Ensembl chr 6:17,636,233...17,666,971

G

carbonic anhydrase 14

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CAR14 mRNA

NCBI chr 3:95,805,080...95,812,443
Ensembl chr 3:95,805,080...95,812,003

G

capping protein regulator and myosin 1 linker 1

decreases expression

chrysene results in decreased expression of CARMIL1 mRNA

NCBI chr13:24,196,464...24,464,983
Ensembl chr13:24,196,327...24,464,778

G

caspase 3

increases activity

chrysene results in increased activity of CASP3 protein

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

G

castor zinc finger 1

increases expression

chrysene results in increased expression of CASZ1 mRNA

NCBI chr 4:148,888,823...149,039,350
Ensembl chr 4:148,888,886...149,039,346

G

catalase

decreases activity

chrysene results in decreased activity of CAT protein

NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505

G

caveolin 1, caveolae protein

decreases expression
multiple interactions

chrysene results in decreased expression of CAV1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CAV1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 6:17,306,387...17,341,323
Ensembl chr 6:17,306,334...17,341,451

G

caveolae associated 1

increases expression

chrysene results in increased expression of CAVIN1 mRNA

NCBI chr11:100,847,562...100,861,443
Ensembl chr11:100,847,559...100,861,713

G

CBFA2/RUNX1 translocation partner 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CBFA2T3 mRNA

NCBI chr 8:123,351,875...123,426,069
Ensembl chr 8:123,351,880...123,425,848

G

collagen and calcium binding EGF domains 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CCBE1 mRNA

NCBI chr18:66,189,926...66,424,909
Ensembl chr18:66,178,373...66,435,812

G

coiled-coil domain containing 184

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CCDC184 mRNA

NCBI chr15:98,065,687...98,068,015
Ensembl chr15:98,065,039...98,068,015

G

coiled-coil domain containing 82

increases expression

chrysene results in increased expression of CCDC82 mRNA

NCBI chr 9:13,246,573...13,292,867
Ensembl chr 9:13,246,536...13,292,867

G

C-C motif chemokine ligand 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CCL4 mRNA

NCBI chr11:83,553,410...83,555,509
Ensembl chr11:83,553,410...83,555,509

G

C-C motif chemokine ligand 5

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CCL5 mRNA

NCBI chr11:83,416,604...83,421,344
Ensembl chr11:83,416,604...83,421,344

G

C-C motif chemokine ligand 6

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CCL6 mRNA

NCBI chr11:83,478,712...83,483,913
Ensembl chr11:83,478,708...83,483,913

G

cerebral cavernous malformation 2-like

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CCM2L mRNA

NCBI chr 2:152,907,857...152,923,655
Ensembl chr 2:152,907,875...152,923,655

G

cyclin D1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CCND1 mRNA

NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662

G

cyclin D2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CCND2 mRNA

NCBI chr 6:127,102,125...127,131,913
Ensembl chr 6:127,102,125...127,129,156

G

cyclin D-type binding-protein 1

decreases expression

chrysene results in decreased expression of CCNDBP1 mRNA

NCBI chr 2:120,838,925...120,847,374
Ensembl chr 2:120,838,884...120,847,385

G

cyclin G1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CCNG1 mRNA

NCBI chr11:40,639,379...40,646,044
Ensembl chr11:40,639,379...40,646,138

G

cyclin J-like

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CCNJL mRNA

NCBI chr11:43,419,576...43,477,826
Ensembl chr11:43,419,611...43,477,824

G

cyclin L1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CCNL1 mRNA

NCBI chr 3:65,853,333...65,869,451
Ensembl chr 3:65,853,572...65,865,670

G

cyclin L2

increases expression

chrysene results in increased expression of CCNL2 mRNA

NCBI chr 4:155,894,468...155,909,005
Ensembl chr 4:155,896,946...155,909,000

G

C-C motif chemokine receptor 7

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CCR7 mRNA

NCBI chr11:99,035,025...99,045,903
Ensembl chr11:99,035,022...99,045,903

G

CD151 antigen

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CD151 mRNA

NCBI chr 7:141,047,275...141,051,394
Ensembl chr 7:141,047,305...141,051,386

G

CD200 molecule

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CD200 mRNA

NCBI chr16:45,202,474...45,229,419
Ensembl chr16:45,202,498...45,229,416

G

CD209c antigen

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CD209C mRNA

NCBI chr 8:3,990,081...4,004,746
Ensembl chr 8:3,990,222...4,004,746

G

CD248 antigen, endosialin

increases expression

chrysene results in increased expression of CD248 mRNA

NCBI chr19:5,118,106...5,120,668
Ensembl chr19:5,118,106...5,120,710

G

CD34 antigen

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CD34 mRNA

NCBI chr 1:194,621,239...194,643,587
Ensembl chr 1:194,621,127...194,643,587

G

CD37 antigen

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CD37 mRNA

NCBI chr 7:44,883,056...44,888,701
Ensembl chr 7:44,883,056...44,888,539

G

CD47 antigen (Rh-related antigen, integrin-associated signal transducer)

decreases expression

chrysene results in decreased expression of CD47 mRNA

NCBI chr16:49,671,691...49,732,799
Ensembl chr16:49,620,896...49,735,373

G

CD48 antigen

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CD48 mRNA

NCBI chr 1:171,508,989...171,532,825
Ensembl chr 1:171,509,577...171,532,826

G

CD55 molecule, decay accelerating factor for complement

increases expression

chrysene results in increased expression of CD55 mRNA

NCBI chr 1:130,357,526...130,390,513
Ensembl chr 1:130,366,764...130,390,481

G

CD69 antigen

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CD69 mRNA

NCBI chr 6:129,244,287...129,252,332
Ensembl chr 6:129,244,288...129,252,399

G

CD79B antigen

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CD79B mRNA

NCBI chr11:106,202,167...106,205,388
Ensembl chr11:106,202,167...106,205,588

G

CD99 antigen

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CD99 mRNA

G

CDC14 cell division cycle 14B

increases expression

chrysene results in increased expression of CDC14B mRNA

NCBI chr13:64,337,085...64,423,670
Ensembl chr13:64,337,082...64,423,104

G

cell division cycle 42

decreases expression

chrysene results in decreased expression of CDC42 mRNA

NCBI chr 4:137,047,011...137,085,007
Ensembl chr 4:137,047,007...137,085,031

G

cadherin 13

increases expression

chrysene results in increased expression of CDH13 mRNA

NCBI chr 8:119,010,150...120,051,668
Ensembl chr 8:119,010,472...120,051,660

G

cadherin 16

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CDH16 mRNA

NCBI chr 8:105,328,547...105,351,028
Ensembl chr 8:105,328,543...105,351,028

G

cadherin 3

increases expression

chrysene results in increased expression of CDH3 mRNA

NCBI chr 8:107,237,484...107,283,543
Ensembl chr 8:107,237,523...107,283,929

G

cadherin-related family member 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CDHR4 mRNA

NCBI chr 9:107,869,656...107,876,880
Ensembl chr 9:107,869,696...107,876,883

G

cyclin dependent kinase 14

decreases expression

chrysene results in decreased expression of CDK14 mRNA

NCBI chr 5:4,853,384...5,430,650
Ensembl chr 5:4,853,391...5,470,312

G

cyclin dependent kinase inhibitor 1A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CDKN1A mRNA

NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701

G

CCAAT/enhancer binding protein delta

decreases expression

chrysene results in decreased expression of CEBPD mRNA

NCBI chr16:15,705,150...15,707,409
Ensembl chr16:15,705,150...15,708,895

G

CUGBP, Elav-like family member 5

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CELF5 mRNA

NCBI chr10:81,295,061...81,318,564
Ensembl chr10:81,295,061...81,318,543

G

cadherin, EGF LAG seven-pass G-type receptor 2

increases expression

chrysene results in increased expression of CELSR2 mRNA

NCBI chr 3:108,298,164...108,323,416
Ensembl chr 3:108,298,167...108,323,383

G

centrosomal protein 162

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CEP162 mRNA

NCBI chr 9:87,071,626...87,137,589
Ensembl chr 9:87,071,630...87,137,589

G

centrosomal protein 41

decreases expression

chrysene results in decreased expression of CEP41 mRNA

NCBI chr 6:30,653,456...30,710,511
Ensembl chr 6:30,653,456...30,693,748

G

centrosomal protein 63

increases expression

chrysene results in increased expression of CEP63 mRNA

NCBI chr 9:102,461,784...102,503,748
Ensembl chr 9:102,461,787...102,503,733

G

carboxyesterase 2B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CES2B mRNA

NCBI chr 8:105,555,130...105,566,725
Ensembl chr 8:105,558,204...105,566,725

G

carboxylesterase 2C

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CES2C mRNA

NCBI chr 8:105,573,700...105,581,115
Ensembl chr 8:105,573,700...105,581,115

G

carboxylesterase 2E

increases expression
multiple interactions

chrysene results in increased expression of CES2E mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CES2E mRNA

PMID:26377693 PMID:27858113

NCBI chr 8:105,652,892...105,661,304
Ensembl chr 8:105,652,892...105,661,304

G

carboxylesterase 2G

increases expression

chrysene results in increased expression of CES2G mRNA

NCBI chr 8:105,688,350...105,696,169
Ensembl chr 8:105,688,350...105,696,169

G

complement factor B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CFB mRNA

NCBI chr17:35,075,350...35,081,492
Ensembl chr17:35,075,350...35,081,494

G

chromodomain helicase DNA binding protein 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CHD2 mRNA

NCBI chr 7:73,076,400...73,191,494
Ensembl chr 7:73,076,386...73,191,578

G

chitinase, acidic 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CHIA mRNA

NCBI chr 3:106,020,698...106,039,434
Ensembl chr 3:106,020,545...106,039,436

G

choline kinase alpha

decreases expression

chrysene results in decreased expression of CHKA mRNA

NCBI chr19:3,901,585...3,944,368
Ensembl chr19:3,901,773...3,944,369

G

carbohydrate sulfotransferase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CHST1 mRNA

NCBI chr 2:92,429,978...92,445,597
Ensembl chr 2:92,430,052...92,445,595

G

cold inducible RNA binding protein

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CIRBP mRNA

NCBI chr10:80,001,824...80,008,620
Ensembl chr10:80,001,819...80,008,620

G

cytokine inducible SH2-containing protein

decreases expression

chrysene results in decreased expression of CISH mRNA

NCBI chr 9:107,173,858...107,179,983
Ensembl chr 9:107,173,225...107,179,983

G

Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CITED2 mRNA

NCBI chr10:17,598,452...17,601,422
Ensembl chr10:17,598,966...17,601,422

G

cytoskeleton associated protein 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CKAP2 mRNA

NCBI chr 8:22,658,168...22,675,835
Ensembl chr 8:22,658,176...22,675,835

G

CLK4-associating serine/arginine rich protein

increases expression

chrysene results in increased expression of SFRS16 mRNA

NCBI chr 7:19,314,963...19,338,442
Ensembl chr 7:19,314,960...19,338,411

G

C-type lectin domain family 1, member a

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CLEC1A mRNA

NCBI chr 6:129,403,647...129,428,963
Ensembl chr 6:129,401,735...129,428,963

G

C-type lectin domain family 2, member f

increases expression

chrysene results in increased expression of CLEC2F mRNA

NCBI chr 6:128,985,766...128,998,305
Ensembl chr 6:128,991,075...128,997,490

G

C-type lectin domain family 2, member h

increases expression

chrysene results in increased expression of CLEC2D mRNA

NCBI chr 6:128,639,348...128,654,337
Ensembl chr 6:128,639,348...128,654,337

G

C-type lectin domain family 4, member a1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CLEC4A1 mRNA

NCBI chr 6:122,898,807...122,911,578
Ensembl chr 6:122,898,807...122,911,578

G

C-type lectin domain family 4, member f

decreases expression

chrysene results in decreased expression of CLEC4F mRNA

NCBI chr 6:83,621,524...83,633,098
Ensembl chr 6:83,621,524...83,633,169

G

C-type lectin domain family 4, member g

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CLEC4G mRNA

NCBI chr 8:3,757,066...3,770,695
Ensembl chr 8:3,757,064...3,770,651

G

CDC like kinase 4

increases expression

chrysene results in increased expression of CLK4 mRNA

NCBI chr11:51,153,941...51,172,597
Ensembl chr11:51,152,557...51,172,593

G

calsyntenin 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CLSTN2 mRNA

NCBI chr 9:97,326,448...97,915,433
Ensembl chr 9:97,326,448...97,915,234

G

cytidine/uridine monophosphate kinase 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CMPK2 mRNA

NCBI chr12:26,519,121...26,529,836
Ensembl chr12:26,519,203...26,529,836

G

cordon-bleu WH2 repeat

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of COBL mRNA

NCBI chr11:12,186,676...12,415,022
Ensembl chr11:12,186,608...12,414,960

G

collagen, type XVII, alpha 1

increases expression

chrysene results in increased expression of COL17A1 mRNA

NCBI chr19:47,634,783...47,680,460
Ensembl chr19:47,634,783...47,680,533

G

collagen, type I, alpha 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of COL1A1 mRNA

NCBI chr11:94,827,050...94,843,868
Ensembl chr11:94,827,050...94,843,868

G

collagen, type I, alpha 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of COL1A2 mRNA

NCBI chr 6:4,505,618...4,541,543
Ensembl chr 6:4,504,814...4,541,544

G

collagen, type XX, alpha 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of COL20A1 mRNA

NCBI chr 2:180,626,629...180,659,338
Ensembl chr 2:180,628,328...180,660,156

G

collagen, type III, alpha 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of COL3A1 mRNA

NCBI chr 1:45,350,698...45,388,866
Ensembl chr 1:45,350,698...45,388,866

G

collagen, type IV, alpha 4

decreases expression
multiple interactions

chrysene results in decreased expression of COL4A4 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of COL4A4 mRNA

PMID:26377693 PMID:27858113

NCBI chr 1:82,426,140...82,564,570
Ensembl chr 1:82,426,144...82,564,570

G

collagen, type IV, alpha 6

increases expression

chrysene results in increased expression of COL4A6 mRNA

NCBI chr X:139,948,399...140,257,091
Ensembl chr X:139,948,399...140,257,072

G

collagen, type V, alpha 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of COL5A3 mRNA

NCBI chr 9:20,681,353...20,726,363
Ensembl chr 9:20,681,346...20,726,363

G

COMM domain containing 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of COMMD3 mRNA

NCBI chr 2:18,677,246...18,681,042
Ensembl chr 2:18,677,234...18,681,042

G

coatomer protein complex, subunit epsilon

decreases expression

chrysene results in decreased expression of COPE mRNA

NCBI chr 8:70,755,417...70,765,652
Ensembl chr 8:70,755,168...70,765,643

G

coordinator of PRMT5, differentiation stimulator

decreases expression

chrysene results in decreased expression of COPRS mRNA

NCBI chr 8:13,934,787...13,940,501
Ensembl chr 8:13,934,794...13,940,281

G

coenzyme Q10B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of COQ10B mRNA

NCBI chr 1:55,091,929...55,111,861
Ensembl chr 1:55,091,929...55,111,861

G

coenzyme Q8A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of COQ8A mRNA

NCBI chr 1:179,992,803...180,023,585
Ensembl chr 1:179,992,803...180,027,167

G

coronin, actin binding protein 2A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CORO2A mRNA

NCBI chr 4:46,536,937...46,601,929
Ensembl chr 4:46,536,937...46,602,202

G

complexin 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CPLX2 mRNA

NCBI chr13:54,455,447...54,531,736
Ensembl chr13:54,519,162...54,531,730
Ensembl chr13:54,519,162...54,531,730

G

copine IV

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CPNE4 mRNA

NCBI chr 9:104,443,900...104,911,747
Ensembl chr 9:104,424,485...104,911,743

G

copine V

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CPNE5 mRNA

NCBI chr17:29,375,495...29,456,764
Ensembl chr17:29,374,530...29,457,141

G

carnitine palmitoyltransferase 1c

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CPT1C mRNA

NCBI chr 7:44,607,907...44,624,304
Ensembl chr 7:44,608,796...44,624,275

G

carboxypeptidase X, M14 family member 2

increases expression

chrysene results in increased expression of CPXM2 mRNA

NCBI chr 7:131,634,416...131,756,483
Ensembl chr 7:131,634,416...131,756,468

G

complement receptor 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CR2 mRNA

NCBI chr 1:194,819,120...194,859,096
Ensembl chr 1:194,819,119...194,859,024

G

cysteine-rich C-terminal 1

increases expression

chrysene results in increased expression of CRCT1 mRNA

NCBI chr 3:92,921,512...92,922,993
Ensembl chr 3:92,921,512...92,922,994

G

cysteine-rich secretory protein LCCL domain containing 2

increases expression

chrysene results in increased expression of CRISPLD2 mRNA

NCBI chr 8:120,719,177...120,779,533
Ensembl chr 8:120,719,177...120,779,532

G

v-crk avian sarcoma virus CT10 oncogene homolog

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CRK mRNA

NCBI chr11:75,570,020...75,599,254
Ensembl chr11:75,570,085...75,597,734

G

colorectal neoplasia differentially expressed, non-protein coding

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CRNDE mRNA

NCBI chr 8:93,052,661...93,082,739
Ensembl chr 8:93,052,659...93,084,247

G

casein kinase 1, gamma 2

increases expression

chrysene results in increased expression of CSNK1G2 mRNA

NCBI chr10:80,458,465...80,476,605
Ensembl chr10:80,458,672...80,476,583

G

cystatin 8 (cystatin-related epididymal spermatogenic)

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CST8 mRNA

NCBI chr 2:148,640,759...148,647,516
Ensembl chr 2:148,640,705...148,647,515

G

cytotoxic T lymphocyte-associated protein 2 beta

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CTLA2B mRNA

NCBI chr13:61,043,165...61,045,269
Ensembl chr13:61,043,164...61,045,261

G

C-X-C motif chemokine ligand 13

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CXCL13 mRNA

NCBI chr 5:96,104,785...96,108,927
Ensembl chr 5:96,104,810...96,108,927

G

C-X-C motif chemokine ligand 15

increases expression
decreases expression
multiple interactions

chrysene results in increased expression of CXCL8 mRNA
chrysene results in decreased expression of CXCL5 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CXCL5 mRNA

PMID:25433334 PMID:26377693 PMID:27858113

NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926

G

C-X-C motif chemokine receptor 5

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CXCR5 mRNA

NCBI chr 9:44,423,084...44,437,741
Ensembl chr 9:44,423,084...44,473,174

G

C-X-C motif chemokine receptor 6

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CXCR6 mRNA

NCBI chr 9:123,635,542...123,640,819
Ensembl chr 9:123,635,540...123,640,825

G

CYLD lysine 63 deubiquitinase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CYLD mRNA

NCBI chr 8:89,423,506...89,478,574
Ensembl chr 8:89,423,675...89,478,573

G

cytochrome P450, family 17, subfamily a, polypeptide 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CYP17A1 mRNA

NCBI chr19:46,655,604...46,661,439
Ensembl chr19:46,655,604...46,661,611

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
increases expression
increases activity
decreases expression

[chrysene binds to and results in increased activity of AHR protein] which results in increased expression of CYP1A1 mRNA; [CYP1A1 protein co-treated with Trichloroepoxypropane] results in increased metabolism of chrysene; alpha-naphthoflavone inhibits the reaction [[chrysene binds to and results in increased activity of AHR protein] which results in increased expression of CYP1A1 mRNA]; chrysene promotes the reaction [AHR protein results in increased expression of CYP1A1 mRNA]; EPHX1 protein promotes the reaction [CYP1A1 protein results in increased metabolism of chrysene]
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CYP1A1 mRNA; [CYP1A1 protein co-treated with Trichloroepoxypropane] results in increased metabolism of chrysene; [fluoranthene co-treated with pyrene co-treated with benz(a)anthracene co-treated with chrysene co-treated with benzo(b)fluoranthene co-treated with benzo(k)fluoranthene co-treated with Benzo(a)pyrene] results in increased expression of CYP1A1 mRNA; EPHX1 protein promotes the reaction [CYP1A1 protein results in increased metabolism of chrysene]
[chrysene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene] promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]; [chrysene co-treated with benz(a)anthracene] promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]; [chrysene co-treated with Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene] results in increased expression of CYP1A1 mRNA; [chrysene co-treated with Benzo(a)pyrene co-treated with benz(a)anthracene] results in increased expression of CYP1A1 mRNA; [chrysene co-treated with Benzo(a)pyrene] results in increased expression of CYP1A1 mRNA; chrysene inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]
chrysene results in increased expression of CYP1A1 mRNA; chrysene results in increased expression of CYP1A1 protein
chrysene results in increased activity of CYP1A1 protein
chrysene results in decreased expression of CYP1A1 mRNA

PMID:7750161 PMID:8961944 PMID:10190573 PMID:12107646 PMID:12117779 More...

NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions
increases expression

[CYP1A2 protein co-treated with Trichloroepoxypropane] results in increased metabolism of chrysene; EPHX1 protein promotes the reaction [CYP1A2 protein results in increased metabolism of chrysene]
[CYP1A2 protein co-treated with Trichloroepoxypropane] results in increased metabolism of chrysene; [fluoranthene co-treated with pyrene co-treated with benz(a)anthracene co-treated with chrysene co-treated with benzo(b)fluoranthene co-treated with benzo(k)fluoranthene co-treated with Benzo(a)pyrene] results in increased expression of CYP1A2 mRNA; EPHX1 protein promotes the reaction [CYP1A2 protein results in increased metabolism of chrysene]
chrysene results in increased expression of CYP1A2 mRNA
[chrysene co-treated with Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene] results in increased expression of CYP1A2 mRNA; [chrysene co-treated with Benzo(a)pyrene co-treated with benz(a)anthracene] results in increased expression of CYP1A2 mRNA; [chrysene co-treated with Benzo(a)pyrene] results in increased expression of CYP1A2 mRNA

PMID:7750161 PMID:8961944 PMID:12107646 PMID:17253728 PMID:31087746 More...

NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986

G

cytochrome P450, family 1, subfamily b, polypeptide 1

multiple interactions
increases expression

[benz(a)anthracene co-treated with benzo(b)fluoranthene] promotes the reaction [chrysene promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 mRNA]]; [chrysene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene] promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 mRNA]; [chrysene co-treated with benz(a)anthracene] promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 mRNA]; [chrysene co-treated with Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene] results in increased expression of CYP1B1 mRNA; [chrysene co-treated with Benzo(a)pyrene co-treated with benz(a)anthracene] results in increased expression of CYP1B1 mRNA; [chrysene co-treated with Benzo(a)pyrene] results in increased expression of CYP1B1 mRNA; chrysene inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 mRNA]; chrysene promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 mRNA]
chrysene results in increased expression of CYP1B1 mRNA
chrysene results in increased expression of CYP1B1 mRNA; chrysene results in increased expression of CYP1B1 protein
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CYP1B1 mRNA

PMID:12107646 PMID:12117779 PMID:15315710 PMID:15566942 PMID:17253728 More...

NCBI chr17:80,014,369...80,022,490
Ensembl chr17:80,008,966...80,022,490

G

cytochrome P450, family 2, subfamily e, polypeptide 1

increases expression

chrysene results in increased expression of CYP2E1 mRNA

NCBI chr 7:140,343,732...140,354,903
Ensembl chr 7:140,343,652...140,354,900

G

cystin 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CYS1 mRNA

NCBI chr12:24,715,832...24,731,794
Ensembl chr12:24,715,832...24,731,812

G

cysteine rich tail 1

increases expression

chrysene results in increased expression of CYSRT1 mRNA

NCBI chr 2:25,128,831...25,129,876
Ensembl chr 2:25,128,830...25,132,464

G

DNA segment, Chr 5, ERATO Doi 579, expressed

increases expression

chrysene results in increased expression of D5ERTD579E mRNA

NCBI chr 5:36,757,827...36,854,083
Ensembl chr 5:36,757,829...36,853,368

G

DNA segment, Chr 5, ERATO Doi 605, expressed

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of D5ERTD605E mRNA

NCBI chr 5:147,355,430...147,359,854
Ensembl chr 5:147,355,411...147,359,860

G

differentiation antagonizing non-protein coding RNA

increases expression

chrysene results in increased expression of DANCR mRNA

NCBI chr 5:74,253,780...74,254,998
Ensembl chr 5:74,253,695...74,256,067

G

aspartyl-tRNA synthetase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DARS1 mRNA

NCBI chr 1:128,291,444...128,345,153
Ensembl chr 1:128,291,444...128,345,105

G

D site albumin promoter binding protein

increases expression
multiple interactions

chrysene results in increased expression of DBP mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DBP mRNA

PMID:26377693 PMID:27858113

NCBI chr 7:45,354,658...45,359,579
Ensembl chr 7:45,354,512...45,359,627

G

DDB1 and CUL4 associated factor 12-like 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DCAF12L2 mRNA

NCBI chr X:43,454,334...43,457,214
Ensembl chr X:43,454,335...43,457,219

G

DDB1 and CUL4 associated factor 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DCAF4 mRNA

NCBI chr12:83,567,145...83,588,768
Ensembl chr12:83,567,240...83,588,694

G

DCC netrin 1 receptor

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DCC mRNA

NCBI chr18:71,386,703...72,484,299
Ensembl chr18:71,386,705...72,484,140

G

decorin

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DCN mRNA

NCBI chr10:97,315,362...97,354,025
Ensembl chr10:97,315,471...97,354,005

G

dimethylarginine dimethylaminohydrolase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DDAH1 mRNA

NCBI chr 3:145,464,447...145,600,032
Ensembl chr 3:145,464,430...145,600,032

G

dopa decarboxylase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DDC mRNA

NCBI chr11:11,764,101...11,848,144
Ensembl chr11:11,764,101...11,848,144

G

DNA damage-induced apoptosis suppressor

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DDIAS mRNA

NCBI chr 7:92,506,734...92,523,455
Ensembl chr 7:92,506,733...92,523,455

G

DNA-damage-inducible transcript 4-like

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DDIT4L mRNA

NCBI chr 3:137,329,433...137,334,093
Ensembl chr 3:137,327,373...137,334,094

G

DEAD box helicase 25

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DDX25 mRNA

NCBI chr 9:35,453,144...35,469,766
Ensembl chr 9:35,447,943...35,469,824

G

DEAD box helicase 5

increases expression
multiple interactions

chrysene results in increased expression of DDX5 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DDX5 mRNA

PMID:26377693 PMID:27858113

NCBI chr11:106,671,181...106,680,011
Ensembl chr11:106,671,181...106,680,011

G

differentially expressed in FDCP 6

increases expression

chrysene results in increased expression of DEF6 mRNA

NCBI chr17:28,426,752...28,447,582
Ensembl chr17:28,426,752...28,447,582

G

diacylglycerol O-acyltransferase 2

increases expression
multiple interactions

chrysene results in increased expression of DGAT2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DGAT2 mRNA

PMID:26377693 PMID:27858113

NCBI chr 7:98,802,870...98,831,920
Ensembl chr 7:98,802,865...98,831,926

G

diacylglycerol kinase, alpha

increases expression

chrysene results in increased expression of DGKA mRNA

NCBI chr10:128,556,000...128,581,002
Ensembl chr10:128,556,003...128,580,724

G

diacylglycerol kinase, theta

increases expression

chrysene results in increased expression of DGKQ mRNA

NCBI chr 5:108,794,910...108,808,696
Ensembl chr 5:108,794,559...108,817,538

G

diaphanous related formin 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DIAP1 mRNA

NCBI chr18:37,976,654...38,068,573
Ensembl chr18:37,976,654...38,068,529

G

dicer 1, ribonuclease type III

increases expression

chrysene results in increased expression of DICER1 mRNA

NCBI chr12:104,654,001...104,718,331
Ensembl chr12:104,654,001...104,718,211

G

death inducer-obliterator 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DIDO1 mRNA

NCBI chr 2:180,299,757...180,351,886
Ensembl chr 2:180,299,757...180,351,792

G

divergent protein kinase domain 1B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DIPK1B mRNA

NCBI chr 2:26,518,469...26,526,509
Ensembl chr 2:26,518,469...26,526,509

G

DIX domain containing 1

decreases expression

chrysene results in decreased expression of DIXDC1 mRNA

NCBI chr 9:50,574,052...50,650,900
Ensembl chr 9:50,574,052...50,650,817

G

cyclin D binding myb like transcription factor 1

decreases expression

chrysene results in decreased expression of DMTF1 mRNA

NCBI chr 5:9,168,868...9,211,782
Ensembl chr 5:9,168,801...9,211,776

G

DnaJ heat shock protein family (Hsp40) member A1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DNAJA1 mRNA

NCBI chr 4:40,722,468...40,734,965
Ensembl chr 4:40,722,150...40,737,149

G

DnaJ heat shock protein family (Hsp40) member B4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DNAJB4 mRNA

NCBI chr 3:151,887,217...151,915,720
Ensembl chr 3:151,884,148...151,915,939

G

DnaJ heat shock protein family (Hsp40) member B5

increases expression

chrysene results in increased expression of DNAJB5 mRNA

NCBI chr 4:42,949,866...42,959,425
Ensembl chr 4:42,949,814...42,959,425

G

DnaJ heat shock protein family (Hsp40) member C8

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DNAJC8 mRNA

NCBI chr 4:132,262,859...132,281,053
Ensembl chr 4:132,262,861...132,281,053

G

dynamin 2

increases expression

chrysene results in increased expression of DNM2 mRNA

NCBI chr 9:21,336,167...21,419,055
Ensembl chr 9:21,336,204...21,419,055

G

dolichyl pyrophosphate phosphatase 1

increases expression

chrysene results in increased expression of DOLPP1 mRNA

NCBI chr 2:30,282,261...30,290,539
Ensembl chr 2:30,282,266...30,290,541

G

denticleless E3 ubiquitin protein ligase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DTL mRNA

NCBI chr 1:191,269,468...191,307,656
Ensembl chr 1:191,269,468...191,307,656

G

deltex 4, E3 ubiquitin ligase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DTX4 mRNA

NCBI chr19:12,443,700...12,479,509
Ensembl chr19:12,443,702...12,478,818

G

Dppa2 upstream binding RNA

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DUBR mRNA

NCBI chr16:50,547,114...50,553,136
Ensembl chr16:50,530,732...50,553,159

G

dual specificity phosphatase 3 (vaccinia virus phosphatase VH1-related)

decreases expression

chrysene results in decreased expression of DUSP3 mRNA

NCBI chr11:101,861,967...101,877,839
Ensembl chr11:101,861,969...101,877,839

G

dishevelled segment polarity protein 3

decreases expression
multiple interactions

chrysene results in decreased expression of DVL3 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DVL3 mRNA

PMID:26377693 PMID:27858113

NCBI chr16:20,335,694...20,352,763
Ensembl chr16:20,335,732...20,352,760

G

DAZ interacting protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DZIP1 mRNA

NCBI chr14:119,112,927...119,162,947
Ensembl chr14:119,112,932...119,162,872

G

extracellular matrix protein 1

increases expression
multiple interactions

chrysene results in increased expression of ECM1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ECM1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 3:95,641,459...95,646,880
Ensembl chr 3:95,641,459...95,646,881

G

endothelin receptor type B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of EDNRB mRNA

NCBI chr14:104,052,055...104,081,764
Ensembl chr14:104,052,061...104,081,838

G

EF hand domain containing 1

increases expression

chrysene results in increased expression of EFHD1 mRNA

NCBI chr 1:87,192,075...87,238,563
Ensembl chr 1:87,192,085...87,238,561

G

ephrin A1

increases expression

chrysene results in increased expression of EFNA1 mRNA

NCBI chr 3:89,179,037...89,188,258
Ensembl chr 3:89,179,040...89,188,449

G

ephrin B1

decreases expression
multiple interactions

chrysene results in decreased expression of EFNB1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of EFNB1 mRNA

PMID:26377693 PMID:27858113

NCBI chr X:98,179,667...98,192,628
Ensembl chr X:98,179,736...98,192,597

G

embryonal Fyn-associated substrate

increases expression

chrysene results in increased expression of EFS mRNA

NCBI chr14:55,154,087...55,164,222
Ensembl chr14:55,153,992...55,163,583

G

EH domain binding protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of EHBP1 mRNA

NCBI chr11:21,955,825...22,237,086
Ensembl chr11:21,955,828...22,292,292

G

EH-domain containing 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of EHD1 mRNA

NCBI chr19:6,326,926...6,350,126
Ensembl chr19:6,326,755...6,350,126

G

EH-domain containing 4

increases expression
multiple interactions

chrysene results in increased expression of EHD4 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of EHD4 mRNA

PMID:26377693 PMID:27858113

NCBI chr 2:119,919,958...119,985,028
Ensembl chr 2:119,919,656...119,985,087

G

eukaryotic translation initiation factor 1

increases expression

chrysene results in increased expression of EIF1 mRNA

NCBI chr11:100,210,775...100,212,925
Ensembl chr11:100,210,711...100,212,922

G

eukaryotic translation initiation factor 3, subunit D

increases expression

chrysene results in increased expression of EIF3D mRNA

NCBI chr15:77,843,201...77,855,006
Ensembl chr15:77,843,198...77,855,013

G

eukaryotic translation initiation factor 4E binding protein 3

increases expression

chrysene results in increased expression of EIF4EBP3 mRNA

NCBI chr18:36,797,113...36,799,377
Ensembl chr18:36,797,113...36,798,970

G

eukaryotic translation initiation factor 4, gamma 1

increases expression

chrysene results in increased expression of EIF4G1 mRNA

NCBI chr16:20,491,457...20,511,633
Ensembl chr16:20,487,063...20,511,634

G

eukaryotic translation initiation factor 4 gamma, 3

increases expression

chrysene results in increased expression of EIF4G3 mRNA

NCBI chr 4:137,719,090...137,934,397
Ensembl chr 4:137,720,333...137,935,819

G

endomucin

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of EMCN mRNA

NCBI chr 3:137,046,824...137,136,830
Ensembl chr 3:137,046,828...137,137,946

G

echinoderm microtubule associated protein like 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of EML1 mRNA

NCBI chr12:108,337,265...108,505,835
Ensembl chr12:108,337,216...108,505,876

G

erythrocyte membrane protein band 4.1

decreases expression
multiple interactions

chrysene results in decreased expression of EPB41 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of EPB41 mRNA

PMID:26377693 PMID:27858113

NCBI chr 4:131,650,724...131,802,824
Ensembl chr 4:131,650,724...131,802,632

G

Eph receptor A1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of EPHA1 mRNA

NCBI chr 6:42,335,421...42,350,249
Ensembl chr 6:42,335,421...42,350,202

G

epoxide hydrolase 1, microsomal

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of EPHX1 mRNA; EPHX1 protein promotes the reaction [CYP1A1 protein results in increased metabolism of chrysene]; EPHX1 protein promotes the reaction [CYP1A2 protein results in increased metabolism of chrysene]

PMID:8961944 PMID:27858113

NCBI chr 1:180,817,121...180,845,134
Ensembl chr 1:180,803,775...180,848,469

G

erythropoietin receptor

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of EPOR mRNA

NCBI chr 9:21,870,193...21,874,915
Ensembl chr 9:21,870,193...21,874,802

G

ermin, ERM-like protein

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ERMN mRNA

NCBI chr 2:57,874,920...57,942,962
Ensembl chr 2:57,935,125...57,942,876

G

estrogen receptor 1 (alpha)

multiple interactions
increases expression

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with chrysene] results in increased expression of ESR1 mRNA
chrysene results in increased expression of ESR1 mRNA

NCBI chr10:4,561,989...4,955,633
Ensembl chr10:4,561,593...4,955,614

G

Ewing sarcoma breakpoint region 1

decreases expression

chrysene results in decreased expression of EWSR1 mRNA

NCBI chr11:5,019,687...5,049,314
Ensembl chr11:5,019,689...5,049,266

G

exocyst complex component 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of EXOC4 mRNA

NCBI chr 6:33,226,025...33,950,914
Ensembl chr 6:33,226,020...33,950,914

G

exocyst complex component 6B

increases expression

chrysene results in increased expression of EXOC6B mRNA

NCBI chr 6:84,595,468...85,046,524
Ensembl chr 6:84,595,469...85,046,495

G

coagulation factor XIII, A1 subunit

increases expression

chrysene results in increased expression of F13A1 mRNA

NCBI chr13:37,051,150...37,234,220
Ensembl chr13:37,051,152...37,234,220

G

coagulation factor V

increases expression

chrysene results in increased expression of F5 mRNA

NCBI chr 1:163,979,396...164,048,539
Ensembl chr 1:163,979,407...164,047,846

G

family with sequence similarity 107, member A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of FAM107A mRNA

NCBI chr14:14,152,166...14,173,503
Ensembl chr14:14,151,750...14,173,499

G

family with sequence similarity 110, member D

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FAM110D mRNA

NCBI chr 4:133,978,413...133,993,528
Ensembl chr 4:133,978,421...133,981,417

G

family with sequence similarity 133, member B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FAM133B mRNA

NCBI chr 5:3,593,833...3,620,548
Ensembl chr 5:3,593,833...3,620,238

G

family with sequence similarity 13, member C

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FAM13C mRNA

NCBI chr10:70,274,981...70,394,566
Ensembl chr10:70,276,311...70,394,566

G

FAM20B, glycosaminoglycan xylosylkinase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FAM20B mRNA

NCBI chr 1:156,506,127...156,547,204
Ensembl chr 1:156,506,102...156,546,656

G

FERM, ARH/RhoGEF and pleckstrin domain protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FARP1 mRNA

NCBI chr14:121,272,563...121,521,156
Ensembl chr14:121,272,612...121,521,156

G

Fas-activated serine/threonine kinase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FASTK mRNA

NCBI chr 5:24,646,036...24,650,280
Ensembl chr 5:24,643,438...24,650,285

G

FAT atypical cadherin 2

increases expression

chrysene results in increased expression of FAT2 mRNA

NCBI chr11:55,141,435...55,228,331
Ensembl chr11:55,141,435...55,227,390

G

F-box protein 2

decreases expression

chrysene results in decreased expression of FBXO2 mRNA

NCBI chr 4:148,244,605...148,250,874
Ensembl chr 4:148,245,078...148,250,881

G

Fc receptor, IgE, low affinity II, alpha polypeptide

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of FCER2A mRNA

NCBI chr 8:3,730,280...3,744,174
Ensembl chr 8:3,731,737...3,744,175

G

ferredoxin-fold anticodon binding domain containing 1

increases expression

chrysene results in increased expression of FDXACB1 mRNA

NCBI chr 9:50,679,538...50,683,981
Ensembl chr 9:50,679,536...50,684,648

G

fibroblast growth factor 9

increases expression

chrysene results in increased expression of FGF9 mRNA

NCBI chr14:58,308,543...58,350,311
Ensembl chr14:58,308,004...58,350,177

G

FGFR1 oncogene partner 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FGFR1OP2 mRNA

NCBI chr 6:146,479,401...146,500,696
Ensembl chr 6:146,478,701...146,500,696

G

fibroblast growth factor receptor 3

increases expression

chrysene results in increased expression of FGFR3 mRNA

NCBI chr 5:33,879,068...33,894,412
Ensembl chr 5:33,879,018...33,894,412

G

forkhead-associated phosphopeptide binding domain 1

increases expression

chrysene results in increased expression of FHAD1 mRNA

NCBI chr 4:141,617,741...141,742,438
Ensembl chr 4:141,617,749...141,742,393

G

fin bud initiation factor homolog (zebrafish)

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FIBIN mRNA

NCBI chr 2:110,191,270...110,193,338
Ensembl chr 2:110,191,262...110,193,528

G

FIG4 phosphoinositide 5-phosphatase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of FIG4 mRNA

NCBI chr10:41,064,168...41,179,237
Ensembl chr10:41,064,168...41,179,256

G

fidgetin-like 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of FIGNL1 mRNA

NCBI chr11:11,737,429...11,758,962
Ensembl chr11:11,737,431...11,758,962

G

FK506 binding protein 1a

decreases expression
multiple interactions

chrysene results in decreased expression of FKBP1A mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FKBP1A mRNA

PMID:26377693 PMID:27858113

NCBI chr 2:151,384,403...151,403,611
Ensembl chr 2:151,384,403...151,403,612

G

FK506 binding protein 3

increases expression

chrysene results in increased expression of FKBP3 mRNA

NCBI chr12:65,109,206...65,120,712
Ensembl chr12:65,109,198...65,120,781

G

flightless I actin binding protein

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FLII mRNA

NCBI chr11:60,604,969...60,618,089
Ensembl chr11:60,604,949...60,618,089

G

flavin containing monooxygenase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FMO1 mRNA

NCBI chr 1:162,657,130...162,694,170
Ensembl chr 1:162,657,130...162,694,179

G

fragile X messenger ribonucleoprotein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FMR1 mRNA

NCBI chr X:67,722,144...67,761,569
Ensembl chr X:67,722,147...67,761,569

G

fibronectin type III domain containing 1

increases expression
multiple interactions

chrysene results in increased expression of FNDC1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FNDC1 mRNA

PMID:26377693 PMID:27858113

NCBI chr17:7,957,401...8,046,158
Ensembl chr17:7,957,401...8,046,134

G

FBJ osteosarcoma oncogene

increases expression

chrysene results in increased expression of FOS mRNA

NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047

G

forkhead box F1

increases expression
multiple interactions

chrysene results in increased expression of FOXF1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of FOXF1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 8:121,811,100...121,814,883
Ensembl chr 8:121,811,125...121,814,883

G

forkhead box S1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FOXS1 mRNA

NCBI chr 2:152,773,818...152,775,128
Ensembl chr 2:152,773,818...152,775,128

G

FSHD region gene 1

decreases expression
multiple interactions

chrysene results in decreased expression of FRG1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FRG1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 8:41,842,218...41,870,179
Ensembl chr 8:41,850,496...41,870,111

G

FERM domain containing 4B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FRMD4B mRNA

NCBI chr 6:97,263,828...97,594,618
Ensembl chr 6:97,263,828...97,594,502

G

fascin actin-bundling protein 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FSCN3 mRNA

NCBI chr 6:28,427,888...28,438,621
Ensembl chr 6:28,427,788...28,438,621

G

FMR1 autosomal homolog 2

increases expression

chrysene results in increased expression of FXR2 mRNA

NCBI chr11:69,523,788...69,544,123
Ensembl chr11:69,523,816...69,544,123

G

FXYD domain-containing ion transport regulator 3

increases expression

chrysene results in increased expression of FXYD3 mRNA

NCBI chr 7:30,769,960...30,776,122
Ensembl chr 7:30,767,597...30,776,129

G

growth factor receptor bound protein 2-associated protein 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GAB3 mRNA

NCBI chr X:74,032,151...74,128,511
Ensembl chr X:74,010,449...74,129,064

G

gamma-aminobutyric acid type A receptor subunit alpha 3

increases expression

chrysene results in increased expression of GABRA3 mRNA

NCBI chr X:71,476,282...71,700,525
Ensembl chr X:71,476,287...71,700,454

G

growth arrest specific 6

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of GAS6 mRNA

NCBI chr 8:13,515,374...13,544,535
Ensembl chr 8:13,515,374...13,544,490

G

golgi associated kinase 1B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of GASK1B mRNA

NCBI chr 3:79,791,795...79,853,585
Ensembl chr 3:79,791,840...79,853,587

G

GATA binding protein 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GATA2 mRNA

NCBI chr 6:88,170,873...88,184,014
Ensembl chr 6:88,170,873...88,184,014

G

GATA zinc finger domain containing 2A

increases expression

chrysene results in increased expression of GATAD2A mRNA

NCBI chr 8:70,359,719...70,450,093
Ensembl chr 8:70,359,726...70,449,034

G

glucagon receptor

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of GCGR mRNA

NCBI chr11:120,420,011...120,429,815
Ensembl chr11:120,421,525...120,429,812

G

GTP cyclohydrolase 1

decreases expression

chrysene results in decreased expression of GCH1 mRNA

NCBI chr14:47,391,352...47,426,870
Ensembl chr14:47,391,352...47,426,870

G

glial cells missing homolog 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GCM1 mRNA

NCBI chr 9:77,959,240...77,972,906
Ensembl chr 9:77,959,206...77,972,906

G

GCN1 activator of EIF2AK4

increases expression

chrysene results in increased expression of GCN1 mRNA

NCBI chr 5:115,703,177...115,760,713
Ensembl chr 5:115,703,313...115,760,713

G

guanine deaminase

increases expression

chrysene results in increased expression of GDA mRNA

NCBI chr19:21,368,671...21,450,025
Ensembl chr19:21,368,671...21,450,809

G

growth differentiation factor 15

decreases expression
multiple interactions

chrysene results in decreased expression of GDF15 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of GDF15 mRNA

PMID:26377693 PMID:27858113

NCBI chr 8:71,082,043...71,085,106
Ensembl chr 8:71,082,043...71,085,106

G

glial cell line derived neurotrophic factor family receptor alpha 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GFRA4 mRNA

NCBI chr 2:130,881,552...130,885,008
Ensembl chr 2:130,881,552...130,885,008

G

gap junction protein, beta 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GJB1 mRNA

NCBI chr X:100,419,982...100,429,235
Ensembl chr X:100,419,984...100,429,235

G

GLIS family zinc finger 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of GLIS2 mRNA

NCBI chr16:4,412,217...4,443,076
Ensembl chr16:4,412,577...4,442,788

G

geminin

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of GMNN mRNA

NCBI chr13:24,935,828...24,954,222
Ensembl chr13:24,935,828...24,945,906

G

G protein subunit alpha i1

increases expression

chrysene results in increased expression of GNAI1 mRNA

NCBI chr 5:18,470,133...18,565,411
Ensembl chr 5:18,470,133...18,565,353

G

G patch domain containing 1

affects expression

chrysene affects the expression of GPATCH1 mRNA

NCBI chr 7:34,975,969...35,017,865
Ensembl chr 7:34,975,961...35,017,865

G

GPI-anchored HDL-binding protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GPIHBP1 mRNA

NCBI chr15:75,468,479...75,470,062
Ensembl chr15:75,468,477...75,471,330

G

G protein-coupled receptor 137B, pseudogene

decreases expression

chrysene results in decreased expression of GPR137B-PS mRNA

NCBI chr13:12,628,954...12,665,284
Ensembl chr13:12,630,627...12,665,175

G

G protein-coupled receptor 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of GPR4 mRNA

NCBI chr 7:18,946,463...18,958,101
Ensembl chr 7:18,946,463...18,958,099

G

GPRIN family member 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GPRIN3 mRNA

NCBI chr 6:59,317,988...59,403,291
Ensembl chr 6:59,324,211...59,403,279

G

growth factor receptor bound protein 10

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GRB10 mRNA

NCBI chr11:11,880,499...11,987,428
Ensembl chr11:11,880,508...11,988,683

G

gene regulated by estrogen in breast cancer protein

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of GREB1 mRNA

NCBI chr12:16,720,616...16,851,395
Ensembl chr12:16,720,616...16,850,887

G

galectin-related inter-fiber protein

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GRIFIN mRNA

NCBI chr 5:140,548,872...140,553,280
Ensembl chr 5:140,548,874...140,550,826

G

GRIP1 associated protein 1

increases expression

chrysene results in increased expression of GRIPAP1 mRNA

NCBI chr X:7,656,009...7,686,805
Ensembl chr X:7,656,004...7,686,806

G

gastrin releasing peptide

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GRP mRNA

NCBI chr18:66,005,826...66,019,670
Ensembl chr18:66,005,891...66,019,667

G

glutathione S-transferase, mu 1

multiple interactions

GSTM1 protein affects the metabolism of [chrysene co-treated with Glutathione]

NCBI chr 3:107,919,566...107,925,289
Ensembl chr 3:107,919,571...107,925,289

G

general transcription factor III C 1

increases expression

chrysene results in increased expression of GTF3C1 mRNA

NCBI chr 7:125,240,126...125,306,860
Ensembl chr 7:125,240,126...125,306,952

G

GTPase, very large interferon inducible 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of GVIN1 mRNA

NCBI chr 7:105,755,742...105,814,547
Ensembl chr 7:105,755,763...105,814,533

G

granzyme A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GZMA mRNA

NCBI chr13:113,230,358...113,237,515
Ensembl chr13:113,230,359...113,237,515

G

histocompatibility 13

decreases expression
multiple interactions

chrysene results in decreased expression of H13 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of H13 mRNA

PMID:26377693 PMID:27858113

NCBI chr 2:152,511,292...152,550,590
Ensembl chr 2:152,511,381...152,550,590

G

H19, imprinted maternally expressed transcript

increases expression

chrysene results in increased expression of H19 mRNA

NCBI chr 7:142,129,267...142,131,883
Ensembl chr 7:142,129,262...142,131,917

G

H1.1 linker histone, cluster member

decreases expression

chrysene results in decreased expression of H1F1 mRNA

NCBI chr13:23,947,651...23,948,395
Ensembl chr13:23,947,649...23,948,389

G

H1.2 linker histone, cluster member

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of H1F2 mRNA

NCBI chr13:23,922,790...23,923,514
Ensembl chr13:23,922,791...23,924,350

G

H1.4 linker histone, cluster member

decreases expression
multiple interactions

chrysene results in decreased expression of H1F4 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of H1F4 mRNA

PMID:26377693 PMID:27858113

NCBI chr13:23,805,760...23,806,541
Ensembl chr13:23,804,612...23,806,541

G

histocompatibility 2, M region locus 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of H2-M2 mRNA

NCBI chr17:37,791,742...37,794,445
Ensembl chr17:37,791,742...37,794,443

G

histocompatibility 2, O region alpha locus

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of H2-OA mRNA

NCBI chr17:34,311,353...34,314,286
Ensembl chr17:34,311,314...34,314,208

G

histocompatibility 2, O region beta locus

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of H2-OB mRNA

NCBI chr17:34,457,879...34,464,882
Ensembl chr17:34,457,877...34,473,388

G

histocompatibility 2, Q region locus 10

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of H2-Q10 mRNA

NCBI chr17:35,780,986...35,785,460
Ensembl chr17:35,780,986...35,785,460

G

H3 clustered histone 7

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of H3C15 mRNA

NCBI chr13:23,728,222...23,729,124
Ensembl chr13:23,728,222...23,729,482

G

H4 clustered histone 14

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of H4C3 mRNA

NCBI chr 3:96,170,250...96,170,633
Ensembl chr 3:96,168,998...96,170,627

G

hydroxyacyl glutathione hydrolase

decreases expression

chrysene results in decreased expression of HAGH mRNA

NCBI chr17:25,056,863...25,083,424
Ensembl chr17:25,059,117...25,083,424

G

hemolytic complement

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HC mRNA

NCBI chr 2:34,873,341...34,958,518
Ensembl chr 2:34,873,343...34,951,450

G

HEAT repeat containing 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HEATR1 mRNA

NCBI chr13:12,410,256...12,453,774
Ensembl chr13:12,409,908...12,455,170

G

hect domain and RLD 4

increases expression

chrysene results in increased expression of HERC4 mRNA

NCBI chr10:63,079,122...63,153,660
Ensembl chr10:63,079,589...63,153,657

G

hypermethylated in cancer 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of HIC1 mRNA

NCBI chr11:75,052,203...75,059,970
Ensembl chr11:75,055,391...75,060,345

G

hypoxia inducible lipid droplet associated

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HILPDA mRNA

NCBI chr 6:29,272,487...29,275,448
Ensembl chr 6:29,272,487...29,275,445

G

hepatic leukemia factor

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of HLF mRNA

NCBI chr11:90,227,361...90,281,745
Ensembl chr11:90,227,362...90,281,721

G

homeobox containing 1

decreases expression

chrysene results in decreased expression of HMBOX1 mRNA

NCBI chr14:65,049,049...65,187,354
Ensembl chr14:65,049,049...65,187,320

G

hemicentin 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HMCN1 mRNA

NCBI chr 1:150,438,251...150,869,568
Ensembl chr 1:150,438,275...150,869,186

G

hemicentin 2

increases expression

chrysene results in increased expression of HMCN2 mRNA

NCBI chr 2:31,204,273...31,350,751
Ensembl chr 2:31,204,427...31,350,750

G

high mobility group box 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HMGB1 mRNA

NCBI chr 5:148,983,512...148,989,867
Ensembl chr 5:148,983,512...149,121,299

G

high-mobility group high mobility group box 1, pseudogene 7

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HMGB1-PS7 mRNA

NCBI chr 7:41,670,149...41,671,427
Ensembl chr 7:41,670,260...41,670,907

G

high-mobility group nucleosome binding domain 5

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HMGN5 mRNA

NCBI chr X:108,048,143...108,056,986
Ensembl chr X:108,048,140...108,057,010

G

hyaluronan mediated motility receptor (RHAMM)

decreases expression

chrysene results in decreased expression of HMMR mRNA

NCBI chr11:40,592,215...40,624,290
Ensembl chr11:40,592,222...40,624,249

G

heterogeneous nuclear ribonucleoprotein A/B

increases expression

chrysene results in increased expression of HNRNPAB mRNA

NCBI chr11:51,490,927...51,497,708
Ensembl chr11:51,490,927...51,497,674

G

heterogeneous nuclear ribonucleoprotein F

increases expression
multiple interactions

chrysene results in increased expression of HNRNPF mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HNRNPF mRNA

PMID:26377693 PMID:27858113

NCBI chr 6:117,877,301...117,902,583
Ensembl chr 6:117,877,285...117,902,583

G

heterogeneous nuclear ribonucleoprotein H1

increases expression

chrysene results in increased expression of HNRNPH1 mRNA

NCBI chr11:50,266,084...50,277,355
Ensembl chr11:50,267,817...50,277,355

G

HPS1, biogenesis of lysosomal organelles complex 3 subunit 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of HPS1 mRNA

NCBI chr19:42,743,629...42,770,013
Ensembl chr19:42,743,544...42,768,417

G

lysine demethylase and nuclear receptor corepressor

increases expression

chrysene results in increased expression of HR mRNA

NCBI chr14:70,789,644...70,810,988
Ensembl chr14:70,789,652...70,810,988

G

hydroxysteroid (17-beta) dehydrogenase 14

increases expression

chrysene results in increased expression of HSD17B14 mRNA

NCBI chr 7:45,204,345...45,216,745
Ensembl chr 7:45,204,317...45,217,176

G

heat shock protein 1A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HSPA1A mRNA

NCBI chr17:35,188,335...35,191,132
Ensembl chr17:35,188,166...35,191,132

G

HIV-1 Tat interactive protein 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of HTATIP2 mRNA

NCBI chr 7:49,408,761...49,423,748
Ensembl chr 7:49,408,863...49,423,723

G

HIV TAT specific factor 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HTATSF1 mRNA

NCBI chr X:56,098,930...56,112,543
Ensembl chr X:56,098,943...56,112,543

G

hormonally upregulated Neu-associated kinase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of HUNK mRNA

NCBI chr16:90,182,550...90,296,443
Ensembl chr16:90,182,901...90,296,441

G

islet cell autoantigen 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ICA1 mRNA

NCBI chr 6:8,630,527...8,778,531
Ensembl chr 6:8,630,527...8,778,488

G

intercellular adhesion molecule 1

increases expression

chrysene results in increased expression of ICAM1 protein

NCBI chr 9:20,927,236...20,940,110
Ensembl chr 9:20,927,281...20,940,113

G

icos ligand

increases expression

chrysene results in increased expression of ICOSL mRNA

NCBI chr10:77,904,921...77,915,359
Ensembl chr10:77,905,136...77,919,747

G

inhibitor of DNA binding 1, HLH protein

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ID1 mRNA

NCBI chr 2:152,578,171...152,579,330
Ensembl chr 2:152,578,171...152,579,330

G

immediate early response 3

increases expression

chrysene results in increased expression of IER3 mRNA

NCBI chr17:36,132,605...36,133,803
Ensembl chr17:36,132,576...36,133,815

G

immediate early response 5

decreases expression
multiple interactions

chrysene results in decreased expression of IER5 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of IER5 mRNA

PMID:26377693 PMID:27858113

NCBI chr 1:154,972,113...154,975,382
Ensembl chr 1:154,972,107...154,975,382

G

interferon induced transmembrane protein 6

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of IFITM6 mRNA

NCBI chr 7:140,595,725...140,596,805
Ensembl chr 7:140,595,612...140,597,837

G

immunoglobulin heavy constant mu

increases expression
multiple interactions

chrysene results in increased expression of IGHM mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of IGHM mRNA

PMID:26377693 PMID:27858113

NCBI chr12:113,382,446...113,386,350
Ensembl chr12:113,382,178...113,386,350

G

immunoglobulin heavy variable V1-62

increases expression

chrysene results in increased expression of IGHV1-62 mRNA

NCBI chr12:115,335,606...115,335,898
Ensembl chr12:115,335,606...115,336,053

G

immunoglobulin heavy variable V1-9

increases expression

chrysene results in increased expression of IGHV1-9 mRNA

NCBI chr12:114,547,189...114,547,482
Ensembl chr12:114,547,189...114,547,622

G

immunoglobulin kappa variable 14-111

increases expression

chrysene results in increased expression of IGKV14-111 mRNA

NCBI chr 6:68,233,388...68,233,853
Ensembl chr 6:68,233,373...68,233,853

G

immunoglobulin kappa chain variable 19-93

increases expression

chrysene results in increased expression of IGKV19-93 mRNA

NCBI chr 6:68,713,281...68,713,748
Ensembl chr 6:68,713,281...68,713,764

G

immunoglobulin kappa variable 3-4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of IGKV3-4 mRNA

NCBI chr 6:70,648,773...70,649,361
Ensembl chr 6:70,648,772...70,649,361

G

immunoglobulin kappa variable 6-15

increases expression

chrysene results in increased expression of IGKV6-15 mRNA

NCBI chr 6:70,383,453...70,383,976
Ensembl chr 6:70,383,453...70,383,976

G

immunoglobulin kappa chain variable 9-120

increases expression

chrysene results in increased expression of IGKV9-120 mRNA

NCBI chr 6:68,026,967...68,027,438
Ensembl chr 6:68,026,967...68,027,440

G

immunoglobulin superfamily, member 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of IGSF3 mRNA

NCBI chr 3:101,284,306...101,370,375
Ensembl chr 3:101,284,399...101,370,375

G

IK cytokine

increases expression

chrysene results in increased expression of IK mRNA

NCBI chr18:36,877,709...36,890,692
Ensembl chr18:36,877,731...36,890,688

G

IKAROS family zinc finger 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of IKZF4 mRNA

NCBI chr10:128,466,708...128,505,668
Ensembl chr10:128,466,712...128,505,227

G

interleukin 18 receptor 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of IL18R1 mRNA

NCBI chr 1:40,504,712...40,540,014
Ensembl chr 1:40,504,712...40,540,014

G

interleukin 6

increases expression

chrysene results in increased expression of IL6 mRNA

NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979

G

interleukin enhancer binding factor 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ILF2 mRNA

NCBI chr 3:90,383,421...90,395,686
Ensembl chr 3:90,383,433...90,395,686

G

inflammation and lipid regulator with UBA-like and NBR1-like domains

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ILRUN mRNA

NCBI chr17:27,970,206...28,039,516
Ensembl chr17:27,970,209...28,039,622

G

inka box actin regulator 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of INKA2 mRNA

NCBI chr 3:105,611,915...105,628,158
Ensembl chr 3:105,611,915...105,628,158

G

INO80 complex subunit B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of INO80B mRNA

NCBI chr 6:83,098,746...83,102,100
Ensembl chr 6:83,098,746...83,102,412

G

IQ motif and Sec7 domain 1

decreases expression

chrysene results in decreased expression of IQSEC1 mRNA

NCBI chr 6:90,636,578...90,965,766
Ensembl chr 6:90,633,070...90,965,667

G

inositol 1,4,5-triphosphate receptor associated 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of IRAG2 mRNA

NCBI chr 6:145,061,357...145,120,655
Ensembl chr 6:145,061,379...145,120,660

G

interferon regulatory factor 2 binding protein-like

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of IRF2BPL mRNA

NCBI chr12:86,927,477...86,931,588
Ensembl chr12:86,927,475...86,931,572

G

integrin alpha 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ITGA1 mRNA

NCBI chr13:115,094,615...115,238,500
Ensembl chr13:115,089,632...115,238,500

G

integrin alpha 7

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ITGA7 mRNA

NCBI chr10:128,769,633...128,794,155
Ensembl chr10:128,769,645...128,794,155

G

integrin alpha X

decreases expression

chrysene results in decreased expression of ITGAX mRNA

NCBI chr 7:127,728,697...127,749,829
Ensembl chr 7:127,728,719...127,749,829

G

integrin beta 1 (fibronectin receptor beta)

decreases expression

chrysene results in decreased expression of ITGB1 mRNA

NCBI chr 8:129,412,135...129,460,060
Ensembl chr 8:129,412,135...129,459,681

G

inter-alpha-trypsin inhibitor, heavy chain 5

increases expression

chrysene results in increased expression of ITIH5 mRNA

NCBI chr 2:10,158,354...10,261,340
Ensembl chr 2:10,158,382...10,261,340

G

inositol 1,4,5-triphosphate receptor 2

increases expression

chrysene results in increased expression of ITPR2 mRNA

NCBI chr 6:146,009,797...146,403,757
Ensembl chr 6:146,009,797...146,403,721

G

jun proto-oncogene

increases expression

chrysene results in increased expression of JUN mRNA

NCBI chr 4:94,937,273...94,940,459
Ensembl chr 4:94,937,271...94,940,459

G

jun B proto-oncogene

increases expression

chrysene results in increased expression of JUNB mRNA

NCBI chr 8:85,703,538...85,705,377
Ensembl chr 8:85,701,113...85,705,347

G

KN motif and ankyrin repeat domains 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of KANK4 mRNA

NCBI chr 4:98,643,129...98,706,295
Ensembl chr 4:98,643,135...98,705,774

G

lysine acetyltransferase 14

increases expression

chrysene results in increased expression of KAT14 mRNA

NCBI chr 2:144,210,952...144,249,595
Ensembl chr 2:144,210,903...144,249,596

G

potassium voltage-gated channel, Isk-related subfamily, gene 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of KCNE3 mRNA

NCBI chr 7:99,825,714...99,834,076
Ensembl chr 7:99,825,709...99,834,076

G

potassium channel tetramerisation domain containing 15

increases expression

chrysene results in increased expression of KCTD15 mRNA

NCBI chr 7:34,336,424...34,354,934
Ensembl chr 7:34,338,439...34,356,157

G

kinesin family member 26B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of KIF26B mRNA

NCBI chr 1:178,356,690...178,766,765
Ensembl chr 1:178,356,690...178,766,765

G

kit ligand

decreases expression
multiple interactions

chrysene results in decreased expression of KITL mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of KITL mRNA

PMID:26377693 PMID:27858113

NCBI chr10:99,851,477...99,936,278
Ensembl chr10:99,851,492...99,936,278

G

kelch-like 18

increases expression

chrysene results in increased expression of KLHL18 mRNA

NCBI chr 9:110,254,994...110,305,768
Ensembl chr 9:110,254,994...110,305,762

G

kelch-like 29

increases expression

chrysene results in increased expression of KLHL29 mRNA

NCBI chr12:5,127,465...5,425,682
Ensembl chr12:5,127,472...5,425,682

G

kelch-like 5

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of KLHL5 mRNA

NCBI chr 5:65,264,894...65,325,490
Ensembl chr 5:65,264,882...65,325,531

G

kelch-like 6

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of KLHL6 mRNA

NCBI chr16:19,765,242...19,801,766
Ensembl chr16:19,765,246...19,801,787

G

kallikrein 1-related peptidase b27

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of KLK1B27 mRNA

NCBI chr 7:43,701,714...43,706,136
Ensembl chr 7:43,701,714...43,706,136

G

killer cell lectin-like receptor, subfamily A, member 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of KLRA1 mRNA

NCBI chr 6:130,340,881...130,363,837
Ensembl chr 6:130,340,880...130,363,837

G

killer cell lectin-like receptor, subfamily A, member 15

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of KLRA15 mRNA

G

killer cell lectin-like receptor, subfamily A, member 16

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of KLRA16 mRNA

G

killer cell lectin-like receptor subfamily A, member 22

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of KLRA22 mRNA

G

killer cell lectin-like receptor, subfamily A, member 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of KLRA4 mRNA

NCBI chr 6:130,020,693...130,044,242
Ensembl chr 6:130,020,694...130,044,234

G

killer cell lectin-like receptor, subfamily A, member 8

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of KLRA8 mRNA

NCBI chr 6:130,092,189...130,106,861
Ensembl chr 6:130,092,189...130,106,861

G

lysine (K)-specific methyltransferase 2D

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of KMT2D mRNA

NCBI chr15:98,729,550...98,771,958
Ensembl chr15:98,729,550...98,769,085

G

lysine methyltransferase 5B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of KMT5B mRNA

NCBI chr19:3,816,436...3,868,303
Ensembl chr19:3,817,421...3,868,303

G

keratin 13

increases expression

chrysene results in increased expression of KRT13 mRNA

NCBI chr11:100,008,153...100,012,392
Ensembl chr11:100,008,153...100,012,392

G

keratin 15

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of KRT15 mRNA

NCBI chr11:100,022,585...100,026,775
Ensembl chr11:100,022,584...100,026,754

G

keratin 4

increases expression

chrysene results in increased expression of KRT4 mRNA

NCBI chr15:101,826,970...101,833,170
Ensembl chr15:101,826,970...101,833,170

G

keratin associated protein 19-5

multiple interactions
decreases expression

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of KRTAP19-4 mRNA
chrysene results in decreased expression of KRTAP19-4 mRNA

PMID:26377693 PMID:27858113

NCBI chr16:88,692,856...88,693,337
Ensembl chr16:88,692,856...88,693,345

G

keratinocyte associated protein 2

decreases expression

chrysene results in decreased expression of KRTCAP2 mRNA

NCBI chr 3:89,153,201...89,157,036
Ensembl chr 3:89,153,273...89,157,213

G

laminin, alpha 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LAMA1 mRNA

NCBI chr17:68,004,129...68,129,640
Ensembl chr17:68,004,254...68,129,642

G

laminin, alpha 5

increases expression

chrysene results in increased expression of LAMA5 mRNA

NCBI chr 2:179,818,166...179,867,652
Ensembl chr 2:179,818,166...179,867,652

G

laminin B1

increases expression

chrysene results in increased expression of LAMB1 mRNA

NCBI chr12:31,315,230...31,379,643
Ensembl chr12:31,315,233...31,379,643

G

lysosomal-associated protein transmembrane 4A

decreases expression

chrysene results in decreased expression of LAPTM4A mRNA

NCBI chr12:8,972,072...8,988,742
Ensembl chr12:8,971,598...8,988,742

G

LARGE xylosyl- and glucuronyltransferase 2

increases expression

chrysene results in increased expression of LARGE2 mRNA

NCBI chr 2:92,195,391...92,201,437
Ensembl chr 2:92,195,391...92,205,214

G

La ribonucleoprotein 4B

increases expression

chrysene results in increased expression of LARP4B mRNA

NCBI chr13:9,143,643...9,224,487
Ensembl chr13:9,143,917...9,224,487

G

LIM and SH3 protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of LASP1 mRNA

NCBI chr11:97,689,748...97,729,591
Ensembl chr11:97,689,826...97,729,590

G

late cornified envelope 1A1

increases expression

chrysene results in increased expression of LCE1A1 mRNA

NCBI chr 3:92,553,839...92,555,614
Ensembl chr 3:92,553,842...92,555,614

G

late cornified envelope 1A2

increases expression

chrysene results in increased expression of LCE1A2 mRNA

NCBI chr 3:92,575,920...92,577,622
Ensembl chr 3:92,575,920...92,577,622

G

late cornified envelope 1C

increases expression

chrysene results in increased expression of LCE1C mRNA

NCBI chr 3:92,586,554...92,588,225
Ensembl chr 3:92,586,554...92,588,225

G

late cornified envelope 3B

increases expression

chrysene results in increased expression of LCE3A mRNA; chrysene results in increased expression of LCE3C mRNA

NCBI chr 3:92,840,286...92,841,404
Ensembl chr 3:92,840,286...92,841,404

G

late cornified envelope 3C

increases expression

chrysene results in increased expression of LCE3B mRNA

NCBI chr 3:92,851,793...92,853,038
Ensembl chr 3:92,851,793...92,853,040

G

late cornified envelope 3D

increases expression

chrysene results in increased expression of LCE3D mRNA

NCBI chr 3:92,864,695...92,865,881
Ensembl chr 3:92,864,697...92,865,812

G

ligand dependent nuclear receptor corepressor-like

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of LCORL mRNA

NCBI chr 5:45,854,523...46,015,213
NCBI chr 5:45,877,009...45,884,920
Ensembl chr 5:45,854,523...46,014,957

G

left right determination factor 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LEFTY1 mRNA

NCBI chr 1:180,762,587...180,765,966
Ensembl chr 1:180,762,587...180,765,965

G

leptin receptor

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LEPR mRNA

NCBI chr 4:101,574,393...101,676,375
Ensembl chr 4:101,574,601...101,672,549

G

lectin, galactose binding, soluble 1

increases expression

chrysene results in increased expression of LGALS1 mRNA

NCBI chr15:78,810,925...78,814,665
Ensembl chr15:78,810,925...78,814,665

G

lipoma HMGIC fusion partner-like 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of LHFPL3 mRNA

NCBI chr 5:22,951,052...23,480,595
Ensembl chr 5:22,951,057...23,480,595

G

lysosomal acid lipase A

decreases expression

chrysene results in decreased expression of LIPA mRNA

NCBI chr19:34,469,716...34,504,874
Ensembl chr19:34,469,718...34,504,874

G

loricrin cornified envelope precursor protein

increases expression

chrysene results in increased expression of LORICRIN mRNA

NCBI chr 3:91,987,578...91,990,447
Ensembl chr 3:91,987,578...91,990,449

G

lipin 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LPIN1 mRNA

NCBI chr12:16,585,670...16,697,020
Ensembl chr12:16,585,670...16,696,967

G

leucine rich repeat containing 45

increases expression

chrysene results in increased expression of LRRC45 mRNA

NCBI chr11:120,604,779...120,611,954
Ensembl chr11:120,604,751...120,611,954

G

leucine rich repeat containing 75B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LRRC75B mRNA

NCBI chr10:75,385,953...75,396,532
Ensembl chr10:75,385,957...75,396,164

G

leucine rich repeat containing 8 family, member B

decreases expression

chrysene results in decreased expression of LRRC8B mRNA

NCBI chr 5:105,563,072...105,637,945
Ensembl chr 5:105,563,641...105,637,940

G

leucine-rich repeat kinase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of LRRK1 mRNA

NCBI chr 7:65,908,493...66,038,089
Ensembl chr 7:65,876,660...66,038,098

G

leucine rich repeat neuronal 4

increases expression

chrysene results in increased expression of LRRN4 mRNA

NCBI chr 2:132,710,436...132,735,930
Ensembl chr 2:132,710,225...132,722,811

G

leucine-rich repeats and transmembrane domains 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LRTM2 mRNA

NCBI chr 6:119,292,094...119,315,009
Ensembl chr 6:119,292,094...119,307,727

G

leukocyte specific transcript 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LST1 mRNA

NCBI chr17:35,404,071...35,407,416
Ensembl chr17:35,404,071...35,407,415

G

leukotriene C4 synthase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LTC4S mRNA

NCBI chr11:50,127,288...50,129,378
Ensembl chr11:50,127,288...50,129,443

G

LTV1 ribosome biogenesis factor

increases expression

chrysene results in increased expression of LTV1 mRNA

NCBI chr10:13,054,341...13,068,881
Ensembl chr10:13,053,884...13,068,912

G

lumican

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of LUM mRNA

NCBI chr10:97,401,363...97,408,565
Ensembl chr10:97,400,990...97,408,565

G

lymphocyte antigen 6 family member A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LY6A mRNA

NCBI chr15:74,866,726...74,869,880
Ensembl chr15:74,866,726...74,869,880

G

lymphocyte antigen 6 family member G

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LY6G mRNA

NCBI chr15:75,027,110...75,030,977
Ensembl chr15:75,027,089...75,030,975

G

lymphatic vessel endothelial hyaluronan receptor 1

increases expression
multiple interactions

chrysene results in increased expression of LYVE1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LYVE1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 7:110,449,814...110,462,160
Ensembl chr 7:110,449,814...110,462,446

G

leucine zipper, putative tumor suppressor family member 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of LZTS3 mRNA

NCBI chr 2:130,474,685...130,484,764
Ensembl chr 2:130,474,759...130,484,723

G

membrane associated guanylate kinase, WW and PDZ domain containing 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MAGI3 mRNA

NCBI chr 3:103,920,575...104,127,722
Ensembl chr 3:103,920,575...104,127,690

G

magnesium transporter 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MAGT1 mRNA

NCBI chr X:105,011,690...105,055,408
Ensembl chr X:105,011,690...105,055,512

G

monoamine oxidase A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MAOA mRNA

NCBI chr X:16,485,937...16,554,051
Ensembl chr X:16,485,937...16,554,057

G

mitogen-activated protein kinase kinase kinase kinase 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MAP4K4 mRNA

NCBI chr 1:39,939,806...40,065,470
Ensembl chr 1:39,940,073...40,065,470

G

macrophage receptor with collagenous structure

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MARCO mRNA

NCBI chr 1:120,402,267...120,432,753
Ensembl chr 1:120,402,267...120,432,753

G

MARVEL (membrane-associating) domain containing 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MARVELD3 mRNA

NCBI chr 8:110,674,541...110,688,837
Ensembl chr 8:110,674,546...110,688,835

G

methionine adenosyltransferase 1A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MAT1A mRNA

NCBI chr14:40,826,969...40,846,385
Ensembl chr14:40,826,992...40,846,369

G

methionine adenosyltransferase 2A

increases expression

chrysene results in increased expression of MAT2A mRNA

NCBI chr 6:72,409,779...72,416,539
Ensembl chr 6:72,409,782...72,416,541

G

membrane bound O-acyltransferase domain containing 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MBOAT2 mRNA

NCBI chr12:24,881,401...25,014,399
Ensembl chr12:24,880,878...25,014,396

G

melanoma cell adhesion molecule

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MCAM mRNA

NCBI chr 9:44,045,958...44,054,024
Ensembl chr 9:44,045,766...44,054,024

G

transformed mouse 3T3 cell double minute 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MDM2 mRNA

NCBI chr10:117,524,780...117,546,663
Ensembl chr10:117,524,780...117,546,663

G

transformed mouse 3T3 cell double minute 4

decreases expression
multiple interactions

chrysene results in decreased expression of MDM4 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MDM4 mRNA

PMID:26377693 PMID:27858113

NCBI chr 1:132,913,843...132,958,325
Ensembl chr 1:132,887,222...132,958,299

G

midasin AAA ATPase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MDN1 mRNA

NCBI chr 4:32,656,867...32,775,217
Ensembl chr 4:32,657,119...32,775,217

G

mediator complex subunit 10

decreases expression

chrysene results in decreased expression of MED10 mRNA

NCBI chr13:69,950,467...69,964,221
Ensembl chr13:69,950,514...69,964,223

G

mediator complex subunit 21

decreases expression

chrysene results in decreased expression of MED21 mRNA

NCBI chr 6:146,544,077...146,552,098
Ensembl chr 6:146,544,045...146,552,230

G

mediator complex subunit 24

increases expression

chrysene results in increased expression of MED24 mRNA

NCBI chr11:98,595,423...98,620,245
Ensembl chr11:98,595,417...98,620,261

G

mediator complex subunit 28

decreases expression

chrysene results in decreased expression of MED28 mRNA

NCBI chr 5:45,677,571...45,686,626
Ensembl chr 5:45,677,571...45,686,618

G

mediator complex subunit 7

decreases expression

chrysene results in decreased expression of MED7 mRNA

NCBI chr11:46,327,742...46,333,548
Ensembl chr11:46,327,752...46,333,548

G

myocyte enhancer factor 2C

increases expression

chrysene results in increased expression of MEF2C mRNA

NCBI chr13:83,652,136...83,815,197
Ensembl chr13:83,652,153...83,815,199

G

maternally expressed 3

increases expression

chrysene results in increased expression of MEG3 mRNA

NCBI chr12:109,506,879...109,538,163
Ensembl chr12:109,506,879...109,538,165

G

microfibrillar-associated protein 1B

decreases expression
multiple interactions

chrysene results in decreased expression of MFAP1B mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MFAP1B mRNA

PMID:26377693 PMID:27858113

NCBI chr 2:121,292,147...121,304,504
Ensembl chr 2:121,290,716...121,304,548

G

microfibrillar-associated protein 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MFAP2 mRNA

NCBI chr 4:140,737,735...140,743,284
Ensembl chr 4:140,737,729...140,743,295

G

microfibrillar-associated protein 4

increases expression
multiple interactions

chrysene results in increased expression of MFAP4 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MFAP4 mRNA

PMID:26377693 PMID:27858113

NCBI chr11:61,376,257...61,379,536
Ensembl chr11:61,376,257...61,379,726

G

MFSD2 lysolipid transporter A, lysophospholipid

increases expression

chrysene results in increased expression of MFSD2A mRNA

NCBI chr 4:122,840,643...122,855,844
Ensembl chr 4:122,840,643...122,854,981

G

mannoside acetylglucosaminyltransferase 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MGAT2 mRNA

NCBI chr12:69,230,932...69,233,547
Ensembl chr12:69,230,931...69,233,544

G

monoglyceride lipase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MGLL mRNA

NCBI chr 6:88,701,397...88,805,342
Ensembl chr 6:88,701,394...88,805,342

G

O-6-methylguanine-DNA methyltransferase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MGMT mRNA

NCBI chr 7:136,496,315...136,732,001
Ensembl chr 7:136,496,343...136,731,995

G

MIA SH3 domain containing

decreases expression

chrysene results in decreased expression of MIA mRNA

NCBI chr 7:26,879,166...26,880,574
Ensembl chr 7:26,879,167...26,880,582

G

microtubule associated monooxygenase, calponin and LIM domain containing -like 1

increases expression

chrysene results in increased expression of MICALL1 mRNA

NCBI chr15:78,992,750...79,021,100
Ensembl chr15:78,993,098...79,021,100

G

mitotic deacetylase associated SANT domain protein

multiple interactions
decreases expression

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MIDEAS mRNA
chrysene results in decreased expression of MIDEAS mRNA

PMID:26377693 PMID:27858113

NCBI chr12:84,195,942...84,265,679
Ensembl chr12:84,195,950...84,265,655

G

antigen identified by monoclonal antibody Ki 67

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MKI67 mRNA

NCBI chr 7:135,291,513...135,318,286
Ensembl chr 7:135,291,513...135,318,090

G

MTOR associated protein, LST8 homolog (S. cerevisiae)

increases expression

chrysene results in increased expression of MLST8 mRNA

NCBI chr17:24,692,524...24,698,722
Ensembl chr17:24,692,525...24,698,052

G

membrane magnesium transporter 1

decreases expression

chrysene results in decreased expression of MMGT1 mRNA

NCBI chr X:55,630,872...55,643,304
Ensembl chr X:55,630,872...55,643,429

G

matrix metallopeptidase 14 (membrane-inserted)

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MMP14 mRNA

NCBI chr14:54,669,055...54,679,913
Ensembl chr14:54,669,069...54,682,821

G

matrix metallopeptidase 8

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MMP8 mRNA

NCBI chr 9:7,558,430...7,568,487
Ensembl chr 9:7,558,457...7,568,486

G

multimerin 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MMRN2 mRNA

NCBI chr14:34,097,461...34,126,244
Ensembl chr14:34,097,422...34,126,244

G

mannose-P-dolichol utilization defect 1

decreases expression

chrysene results in decreased expression of MPDU1 mRNA

NCBI chr11:69,547,523...69,553,475
Ensembl chr11:69,547,523...69,553,468

G

macrophage expressed gene 1

decreases expression
multiple interactions

chrysene results in decreased expression of MPEG1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MPEG1 mRNA

PMID:26377693 PMID:27858113

NCBI chr19:12,438,134...12,442,649
Ensembl chr19:12,438,143...12,442,649

G

MPV17 mitochondrial membrane protein-like 2

decreases expression

chrysene results in decreased expression of MPV17L2 mRNA

NCBI chr 8:71,211,295...71,213,589
Ensembl chr 8:71,211,295...71,213,592

G

membrane-spanning 4-domains, subfamily A, member 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MS4A1 mRNA

NCBI chr19:11,227,043...11,243,513
Ensembl chr19:11,227,039...11,243,605

G

membrane-spanning 4-domains, subfamily A, member 4C

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MS4A4C mRNA

NCBI chr19:11,382,081...11,404,610
Ensembl chr19:11,382,134...11,404,610

G

mesothelin

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MSLN mRNA

NCBI chr17:25,967,587...25,973,352
Ensembl chr17:25,967,587...25,973,352

G

macrophage scavenger receptor 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MSR1 mRNA

NCBI chr 8:39,996,284...40,095,790
Ensembl chr 8:40,034,726...40,095,714

G

macrophage stimulating 1 receptor (c-met-related tyrosine kinase)

increases expression

chrysene results in increased expression of MST1R mRNA

NCBI chr 9:107,784,057...107,797,582
Ensembl chr 9:107,784,072...107,797,582

G

NADH dehydrogenase 4L, mitochondrial

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ND4L mRNA

NCBI chr MT:9,877...10,173
Ensembl chr MT:9,877...10,173

G

NADH dehydrogenase 6, mitochondrial

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ND6 mRNA

NCBI chr MT:13,552...14,070
Ensembl chr MT:13,552...14,070

G

metallothionein 1

increases expression

chrysene results in increased expression of MT1 mRNA

NCBI chr 8:94,905,214...94,906,955
Ensembl chr 8:94,905,710...94,906,955

G

metallothionein 2

increases expression

chrysene results in increased expression of MT2 mRNA

NCBI chr 8:94,899,246...94,900,195
Ensembl chr 8:94,899,292...94,900,196

G

mitochondrial fission regulator 1

decreases expression

chrysene results in decreased expression of MTFR1 mRNA

NCBI chr 3:19,241,481...19,274,981
Ensembl chr 3:19,241,491...19,274,981

G

methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MTHFD1L mRNA

NCBI chr10:3,918,282...4,117,081
Ensembl chr10:3,923,118...4,117,081

G

myotubularin related protein 10

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MTMR10 mRNA

NCBI chr 7:63,937,443...63,990,556
Ensembl chr 7:63,937,401...63,990,554

G

mucin 16

increases expression

chrysene results in increased expression of MUC16 mRNA

NCBI chr 9:18,406,741...18,586,117
Ensembl chr 9:18,406,751...18,585,826

G

myeloid-associated differentiation marker

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MYADM mRNA

NCBI chr 7:3,337,563...3,347,871
Ensembl chr 7:3,337,605...3,348,958

G

myosin binding protein C, slow-type

increases expression

chrysene results in increased expression of MYBPC1 mRNA

NCBI chr10:88,354,141...88,441,051
Ensembl chr10:88,354,141...88,441,014

G

myosin, heavy polypeptide 1, skeletal muscle, adult

increases expression

chrysene results in increased expression of MYH1 mRNA

NCBI chr11:67,090,922...67,115,401
Ensembl chr11:67,090,878...67,115,401

G

myosin, heavy polypeptide 4, skeletal muscle

increases expression

chrysene results in increased expression of MYH4 mRNA

NCBI chr11:67,128,638...67,151,273
Ensembl chr11:67,128,855...67,151,272

G

myosin, light polypeptide 6, alkali, smooth muscle and non-muscle

increases expression

chrysene results in increased expression of MYL6 mRNA

NCBI chr10:128,326,728...128,329,755
Ensembl chr10:128,326,729...128,330,014

G

myosin, light polypeptide kinase

increases expression

chrysene results in increased expression of MYLK mRNA

NCBI chr16:34,565,569...34,822,806
Ensembl chr16:34,565,580...34,822,790

G

myosin IG

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MYO1G mRNA

NCBI chr11:6,456,548...6,470,960
Ensembl chr11:6,456,548...6,470,965

G

myomesin family, member 3

increases expression

chrysene results in increased expression of MYOM3 mRNA

NCBI chr 4:135,486,688...135,542,882
Ensembl chr 4:135,487,026...135,542,875

G

myozenin 1

increases expression

chrysene results in increased expression of MYOZ1 mRNA

NCBI chr14:20,699,170...20,706,608
Ensembl chr14:20,699,175...20,706,608

G

N-acetyltransferase 8 (GCN5-related)

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NAT8 mRNA

NCBI chr 6:85,807,369...85,813,839
Ensembl chr 6:85,807,370...85,809,064

G

neurobeachin like 1

decreases expression

chrysene results in decreased expression of NBEAL1 mRNA

NCBI chr 1:60,217,910...60,377,487
Ensembl chr 1:60,219,758...60,377,487

G

non-SMC condensin I complex, subunit H

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NCAPH mRNA

NCBI chr 2:126,945,729...126,975,857
Ensembl chr 2:126,945,729...126,975,874

G

nuclear cap binding protein subunit 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NCBP2 mRNA

NCBI chr16:31,767,364...31,777,290
Ensembl chr16:31,767,331...31,780,599

G

nuclear cap binding subunit 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NCBP3 mRNA

NCBI chr11:72,937,443...72,974,405
Ensembl chr11:72,938,609...72,980,143

G

nuclear receptor coactivator 3

increases expression

chrysene results in increased expression of NCOA3 mRNA

NCBI chr 2:165,834,557...165,915,162
Ensembl chr 2:165,834,545...165,915,162

G

NDC80 kinetochore complex component

decreases expression

chrysene results in decreased expression of NDC80 mRNA

NCBI chr17:71,803,095...71,833,852
Ensembl chr17:71,803,095...71,833,852

G

NADH:ubiquinone oxidoreductase subunit B6

decreases expression

chrysene results in decreased expression of NDUFB6 mRNA

NCBI chr 4:40,270,591...40,279,421
Ensembl chr 4:40,270,591...40,279,421

G

nuclear paraspeckle assembly transcript 1 (non-protein coding)

increases expression

chrysene results in increased expression of NEAT1 mRNA

NCBI chr19:5,874,736...5,895,508
Ensembl chr19:5,874,736...5,895,898

G

nebulin

increases expression

chrysene results in increased expression of NEB mRNA

NCBI chr 2:52,026,652...52,228,810
Ensembl chr 2:52,026,659...52,268,486

G

nectin cell adhesion molecule 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PVRL1 mRNA

NCBI chr 9:43,655,251...43,718,758
Ensembl chr 9:43,655,281...43,743,955

G

neuraminidase 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NEU2 mRNA

NCBI chr 1:87,501,749...87,525,567
Ensembl chr 1:87,437,611...87,525,567

G

nexilin

increases expression

chrysene results in increased expression of NEXN mRNA

NCBI chr 3:151,942,619...151,972,000
Ensembl chr 3:151,942,619...151,971,987

G

nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NFATC1 mRNA

NCBI chr18:80,649,418...80,756,286
Ensembl chr18:80,649,420...80,756,286

G

nuclear factor, erythroid derived 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NFE2 mRNA

NCBI chr15:103,156,640...103,166,809
Ensembl chr15:103,156,639...103,166,830

G

nuclear factor, interleukin 3, regulated

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NFIL3 mRNA

NCBI chr13:53,121,245...53,136,914
Ensembl chr13:53,121,245...53,135,109

G

nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha

decreases expression

chrysene results in decreased expression of NFKBIA mRNA

NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432

G

nerve growth factor receptor (TNFR superfamily, member 16)

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TNFRSF10B mRNA

NCBI chr11:95,459,644...95,478,524
Ensembl chr11:95,459,644...95,478,561

G

NHL repeat containing 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NHLRC2 mRNA

NCBI chr19:56,536,682...56,591,935
Ensembl chr19:56,536,693...56,591,935

G

NHS like 1

increases expression

chrysene results in increased expression of NHSL1 mRNA

NCBI chr10:18,193,419...18,409,640
Ensembl chr10:18,194,733...18,409,640

G

natural killer tumor recognition sequence

decreases expression
multiple interactions

chrysene results in decreased expression of NKTR mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NKTR mRNA

PMID:26377693 PMID:27858113

NCBI chr 9:121,542,244...121,585,908
Ensembl chr 9:121,548,235...121,585,909

G

NOC2 like nucleolar associated transcriptional repressor

increases expression

chrysene results in increased expression of NOC2L mRNA

NCBI chr 4:156,319,112...156,332,078
Ensembl chr 4:156,320,376...156,332,073

G

non-POU-domain-containing, octamer binding protein

increases expression

chrysene results in increased expression of NONO mRNA

NCBI chr X:100,473,295...100,492,193
Ensembl chr X:100,472,924...100,492,197

G

NOP2 nucleolar protein

increases expression

chrysene results in increased expression of NOP2 mRNA

NCBI chr 6:125,108,829...125,121,716
Ensembl chr 6:125,108,872...125,121,716

G

notch 1

decreases expression
multiple interactions

chrysene results in decreased expression of NOTCH1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NOTCH1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 2:26,347,914...26,393,834
Ensembl chr 2:26,347,915...26,406,675

G

NADPH oxidase activator 1

decreases expression

chrysene results in decreased expression of NOXA1 mRNA

NCBI chr 2:24,975,679...24,985,217
Ensembl chr 2:24,975,679...24,985,161

G

nephronophthisis 1 (juvenile) homolog (human)

decreases expression
multiple interactions

chrysene results in decreased expression of NPHP1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NPHP1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 2:127,582,652...127,630,833
Ensembl chr 2:127,582,652...127,630,817

G

nucleophosmin 1

increases expression

chrysene results in increased expression of NPM1 mRNA

NCBI chr11:33,102,498...33,114,143
Ensembl chr11:33,102,287...33,113,206

G

natriuretic peptide receptor 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NPR3 mRNA

NCBI chr15:11,839,982...11,907,287
Ensembl chr15:11,839,982...11,907,373

G

neuropeptide Y receptor Y1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NPY1R mRNA

NCBI chr 8:67,149,595...67,159,452
Ensembl chr 8:67,149,844...67,159,444

G

NAD(P)H dehydrogenase, quinone 1

increases activity

chrysene results in increased activity of NQO1 protein

NCBI chr 8:108,114,856...108,139,012
Ensembl chr 8:108,114,857...108,129,838

G

nuclear receptor subfamily 1, group D, member 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NR1D1 mRNA

NCBI chr11:98,658,758...98,666,233
Ensembl chr11:98,658,758...98,666,159

G

nuclear receptor subfamily 1, group D, member 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NR1D2 mRNA

NCBI chr14:4,230,549...4,265,639
Ensembl chr14:4,230,569...4,265,642

G

nuclear receptor binding protein 2

increases expression

chrysene results in increased expression of NRBP2 mRNA

NCBI chr15:75,957,364...75,963,539
Ensembl chr15:75,957,367...75,963,476

G

neuronal cell adhesion molecule

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NRCAM mRNA

NCBI chr12:44,375,568...44,651,977
Ensembl chr12:44,375,668...44,648,747

G

nuclear receptor-binding SET-domain protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NSD1 mRNA

NCBI chr13:55,357,595...55,466,138
Ensembl chr13:55,357,595...55,466,138

G

NSFL1 (p97) cofactor (p47)

increases expression

chrysene results in increased expression of NSFL1C mRNA

NCBI chr 2:151,336,102...151,353,230
Ensembl chr 2:151,336,102...151,353,334

G

5'-nucleotidase domain containing 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NT5DC2 mRNA

NCBI chr14:30,853,046...30,861,081
Ensembl chr14:30,853,010...30,861,081

G

netrin 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NTN1 mRNA

NCBI chr11:68,100,190...68,277,652
Ensembl chr11:68,100,190...68,291,649

G

nuclear FMR1 interacting protein 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NUFIP2 mRNA

NCBI chr11:77,576,566...77,608,792
Ensembl chr11:77,576,981...77,632,747

G

nucleoporin 85

increases expression

chrysene results in increased expression of NUP85 mRNA

NCBI chr11:115,455,264...115,474,750
Ensembl chr11:115,455,260...115,474,811

G

nuclear RNA export factor 1

increases expression

chrysene results in increased expression of NXF1 mRNA

NCBI chr19:8,734,467...8,748,274
Ensembl chr19:8,734,437...8,748,286

G

nucleoredoxin

increases expression

chrysene results in increased expression of NXN mRNA

NCBI chr11:76,148,052...76,289,967
Ensembl chr11:76,148,024...76,289,966

G

neurexophilin 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NXPH3 mRNA

NCBI chr11:95,400,671...95,405,380
Ensembl chr11:95,400,671...95,405,396

G

O-GlcNAcase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of OGA mRNA

NCBI chr19:45,738,698...45,772,274
Ensembl chr19:45,738,698...45,772,276

G

olfactory receptor family 13 subfamily L member 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of OR13L2 mRNA

NCBI chr 3:97,317,533...97,318,495
Ensembl chr 3:97,314,766...97,329,336

G

olfactory receptor family 55 subfamily B member 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of OR55B4 mRNA

NCBI chr 7:102,133,321...102,137,514
Ensembl chr 7:102,131,238...102,137,520

G

orosomucoid 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ORM3 mRNA

NCBI chr 4:63,274,107...63,277,748
Ensembl chr 4:63,274,399...63,277,748

G

purinergic receptor P2X, ligand-gated ion channel, 7

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of P2RX7 mRNA

NCBI chr 5:122,781,990...122,830,399
Ensembl chr 5:122,781,974...122,829,495

G

proliferation-associated 2G4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PA2G4 mRNA

NCBI chr10:128,393,635...128,401,803
Ensembl chr10:128,393,635...128,401,856

G

poly(A)binding protein nuclear 1-like

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PABPN1L mRNA

NCBI chr 8:123,346,210...123,349,474
Ensembl chr 8:123,346,210...123,349,478

G

Paf1, RNA polymerase II complex component

increases expression

chrysene results in increased expression of PAF1 mRNA

NCBI chr 7:28,074,998...28,098,813
Ensembl chr 7:28,092,376...28,098,813

G

phenylalanine hydroxylase

decreases expression

chrysene results in decreased expression of PAH mRNA

NCBI chr10:87,357,657...87,419,999
Ensembl chr10:87,357,657...87,419,998

G

palmdelphin

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PALMD mRNA

NCBI chr 3:116,711,911...116,762,896
Ensembl chr 3:116,711,907...116,762,636

G

PAN3 poly(A) specific ribonuclease subunit

increases expression

chrysene results in increased expression of PAN3 mRNA

NCBI chr 5:147,363,018...147,485,310
Ensembl chr 5:147,366,971...147,485,312

G

pantothenate kinase 4

increases expression

chrysene results in increased expression of PANK4 mRNA

NCBI chr 4:155,048,580...155,065,395
Ensembl chr 4:155,048,580...155,065,395

G

poly (A) polymerase alpha

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PAPOLA mRNA

NCBI chr12:105,750,926...105,805,208
Ensembl chr12:105,750,953...105,805,203

G

prostate androgen-regulated mucin-like protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PARM1 mRNA

NCBI chr 5:91,665,559...91,771,870
Ensembl chr 5:91,665,474...91,774,753

G

PDZ binding kinase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PBK mRNA

NCBI chr14:66,043,337...66,055,271
Ensembl chr14:66,043,286...66,055,271

G

pre B cell leukemia homeobox 1

decreases expression
multiple interactions

chrysene results in decreased expression of PBX1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PBX1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 1:167,946,933...168,259,898
Ensembl chr 1:167,946,933...168,259,839

G

protocadherin 17

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PCDH17 mRNA

NCBI chr14:84,680,626...84,775,005
Ensembl chr14:84,681,003...84,776,442

G

protocadherin alpha subfamily C, 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PCDHAC2 mRNA

NCBI chr18:37,276,731...37,320,716
Ensembl chr18:37,276,556...37,320,710

G

protocadherin gamma subfamily A, 9

decreases expression
multiple interactions

chrysene results in decreased expression of PCDHGA9 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PCDHGA9 mRNA

PMID:26377693 PMID:27858113

NCBI chr18:37,869,989...37,974,916
Ensembl chr18:37,869,989...37,974,923

G

Purkinje cell protein 2 (L7)

increases expression

chrysene results in increased expression of PCP2 mRNA

NCBI chr 8:3,673,369...3,675,547
Ensembl chr 8:3,673,371...3,675,545

G

PDGFA associated protein 1

increases expression

chrysene results in increased expression of PDAP1 mRNA

NCBI chr 5:145,065,580...145,076,835
Ensembl chr 5:145,065,579...145,077,048

G

phosphodiesterase 4A, cAMP specific

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PDE4A mRNA

NCBI chr 9:21,076,998...21,124,544
Ensembl chr 9:21,073,005...21,124,544

G

pyruvate dehydrogenase kinase, isoenzyme 2

increases expression

chrysene results in increased expression of PDK2 mRNA

NCBI chr11:94,917,084...94,932,197
Ensembl chr11:94,917,084...94,932,180

G

pyridoxal (pyridoxine, vitamin B6) kinase

decreases expression

chrysene results in decreased expression of PDXK mRNA

NCBI chr10:78,272,581...78,300,782
Ensembl chr10:78,272,578...78,300,809

G

phosphatidylethanolamine binding protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PEBP1 mRNA

NCBI chr 5:117,420,716...117,425,629
Ensembl chr 5:117,420,719...117,425,690

G

platelet/endothelial cell adhesion molecule 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PECAM1 mRNA

NCBI chr11:106,545,039...106,606,107
Ensembl chr11:106,545,043...106,641,454

G

period circadian clock 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PER1 mRNA

NCBI chr11:68,985,934...69,000,791
Ensembl chr11:68,986,043...69,000,786

G

period circadian clock 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PER2 mRNA

NCBI chr 1:91,343,699...91,387,028
Ensembl chr 1:91,343,704...91,387,046

G

period circadian clock 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PER3 mRNA

NCBI chr 4:151,081,475...151,129,167
Ensembl chr 4:151,088,109...151,129,122

G

6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PFKFB3 mRNA

NCBI chr 2:11,476,241...11,558,882
Ensembl chr 2:11,476,244...11,558,888

G

post-GPI attachment to proteins 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PGAP2 mRNA

NCBI chr 7:101,859,153...101,887,771
Ensembl chr 7:101,859,415...101,887,774

G

PHD finger protein 19

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PHF19 mRNA

NCBI chr 2:34,783,764...34,804,365
Ensembl chr 2:34,783,769...34,804,038

G

PHD finger protein 20-like 1

decreases expression

chrysene results in decreased expression of PHF20L1 mRNA

NCBI chr15:66,449,354...66,519,821
Ensembl chr15:66,449,409...66,519,825

G

PHD finger protein 21A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PHF21A mRNA

NCBI chr 2:92,014,096...92,195,011
Ensembl chr 2:92,014,451...92,195,011

G

pleckstrin homology like domain, family A, member 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PHLDA3 mRNA

NCBI chr 1:135,693,823...135,696,872
Ensembl chr 1:135,693,857...135,696,874

G

PH domain and leucine rich repeat protein phosphatase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PHLPP1 mRNA

NCBI chr 1:106,099,599...106,321,975
Ensembl chr 1:106,099,482...106,321,980

G

phytanoyl-CoA hydroxylase interacting protein

increases expression

chrysene results in increased expression of PHYHIP mRNA

NCBI chr14:70,694,957...70,706,266
Ensembl chr14:70,694,916...70,706,272

G

piezo-type mechanosensitive ion channel component 1

increases expression

chrysene results in increased expression of PIEZO1 mRNA

NCBI chr 8:123,208,437...123,278,068
Ensembl chr 8:123,208,437...123,278,068

G

polymeric immunoglobulin receptor

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PIGR mRNA

NCBI chr 1:130,754,421...130,779,986
Ensembl chr 1:130,754,421...130,779,986

G

proviral integration site 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PIM1 mRNA

NCBI chr17:29,709,759...29,715,085
Ensembl chr17:29,709,727...29,715,086

G

PICALM interacting mitotic regulator

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PIMREG mRNA

NCBI chr11:71,932,867...71,938,197
Ensembl chr11:71,932,858...71,938,196

G

PIN2/TERF1 interacting, telomerase inhibitor 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PINX1 mRNA

NCBI chr14:64,097,728...64,157,311
Ensembl chr14:64,097,813...64,157,308

G

phosphatidylinositol-4,5-bisphosphate 4-phosphatase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PIP4P1 mRNA

NCBI chr14:51,164,672...51,168,306
Ensembl chr14:51,163,525...51,168,313

G

protein kinase inhibitor, alpha

increases expression

chrysene results in increased expression of PKIA mRNA

NCBI chr 3:7,431,695...7,510,426
Ensembl chr 3:7,431,729...7,510,426

G

protein kinase inhibitor, gamma

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PKIG mRNA

NCBI chr 2:163,500,306...163,568,078
Ensembl chr 2:163,500,306...163,568,078

G

protein kinase N3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PKN3 mRNA

NCBI chr 2:29,967,657...29,981,031
Ensembl chr 2:29,967,696...29,981,034

G

placenta-specific 8

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PLAC8 mRNA

NCBI chr 5:100,699,455...100,720,119
Ensembl chr 5:100,701,591...100,720,111

G

pleiomorphic adenoma gene-like 2

increases expression

chrysene results in increased expression of PLAGL2 mRNA

NCBI chr 2:153,069,689...153,083,278
Ensembl chr 2:153,069,679...153,083,346

G

plasminogen activator, tissue

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PLAT mRNA

NCBI chr 8:23,247,655...23,272,864
Ensembl chr 8:23,247,743...23,272,860

G

phospholipase C, beta 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PLCB1 mRNA

NCBI chr 2:134,628,084...135,317,178
Ensembl chr 2:134,627,987...135,317,178

G

phospholipase C, delta 1

increases expression

chrysene results in increased expression of PLCD1 mRNA

NCBI chr 9:118,900,595...118,922,570
Ensembl chr 9:118,900,595...118,922,570

G

phospholipase C, delta 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PLCD4 mRNA

NCBI chr 1:74,581,175...74,605,137
Ensembl chr 1:74,582,047...74,606,953

G

phospholipase C, eta 2

increases expression

chrysene results in increased expression of PLCH2 mRNA

NCBI chr 4:155,067,572...155,148,548
Ensembl chr 4:155,067,572...155,141,241

G

pleckstrin homology domain containing, family G (with RhoGef domain) member 6

increases expression

chrysene results in increased expression of PLEKHG6 mRNA

NCBI chr 6:125,339,614...125,358,578
Ensembl chr 6:125,339,623...125,357,756

G

pleckstrin homology domain containing, family H (with MyTH4 domain) member 3

increases expression

chrysene results in increased expression of PLEKHH3 mRNA

NCBI chr11:101,053,505...101,062,205
Ensembl chr11:101,053,505...101,062,177

G

polo like kinase 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PLK2 mRNA

NCBI chr13:110,531,578...110,537,378
Ensembl chr13:110,531,580...110,537,378

G

polo like kinase 5

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PLK5 mRNA

NCBI chr10:80,192,293...80,201,323
Ensembl chr10:80,192,293...80,201,323

G

phospholipid phosphatase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PPAP2A mRNA

NCBI chr13:112,937,311...113,004,428
Ensembl chr13:112,937,326...113,004,428

G

phospholipid scramblase 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PLSCR2 mRNA

NCBI chr 9:92,157,655...92,179,805
Ensembl chr 9:92,157,655...92,179,805

G

phorbol-12-myristate-13-acetate-induced protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PMAIP1 mRNA

NCBI chr18:66,591,675...66,598,629
Ensembl chr18:66,591,604...66,598,636

G

peripheral myelin protein 22

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PMP22 mRNA

NCBI chr11:63,019,808...63,050,373
Ensembl chr11:63,019,808...63,050,373

G

pregnancy upregulated non-ubiquitously expressed CaM kinase

increases expression

chrysene results in increased expression of PNCK mRNA

NCBI chr X:72,699,598...72,703,723
Ensembl chr X:72,699,600...72,703,723

G

paraneoplastic antigen MA2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PNMA2 mRNA

NCBI chr14:67,139,038...67,157,512
Ensembl chr14:67,148,619...67,158,472

G

polymerase (DNA-directed), delta interacting protein 3

increases expression

chrysene results in increased expression of POLDIP3 mRNA

NCBI chr15:83,010,169...83,033,579
Ensembl chr15:83,010,177...83,033,585

G

polymerase (DNA directed), kappa

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of POLK mRNA

NCBI chr13:96,617,195...96,679,087
Ensembl chr13:96,617,198...96,679,087

G

proteasome maturation protein

decreases expression

chrysene results in decreased expression of POMP mRNA

NCBI chr 5:147,797,438...147,812,594
Ensembl chr 5:147,797,271...147,813,266

G

paraoxonase 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PON2 mRNA

NCBI chr 6:5,264,620...5,298,408
Ensembl chr 6:5,264,147...5,298,455

G

POU domain, class 2, associating factor 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of POU2AF1 mRNA

NCBI chr 9:51,124,990...51,151,379
Ensembl chr 9:51,125,008...51,151,380

G

protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 3

increases expression

chrysene results in increased expression of PPFIA3 mRNA

NCBI chr 7:44,988,550...45,016,443
Ensembl chr 7:44,988,546...45,016,443

G

peptidyl-prolyl isomerase G (cyclophilin G)

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PPIG mRNA

NCBI chr 2:69,553,152...69,584,356
Ensembl chr 2:69,552,889...69,584,356

G

protein phosphatase 1A, magnesium dependent, alpha isoform

decreases expression

chrysene results in decreased expression of PPM1A mRNA

NCBI chr12:72,804,231...72,846,593
Ensembl chr12:72,804,229...72,846,593

G

prickle planar cell polarity protein 3

increases expression

chrysene results in increased expression of PRICKLE3 mRNA

NCBI chr X:7,523,616...7,535,086
Ensembl chr X:7,523,499...7,534,425

G

protein kinase, AMP-activated, gamma 3 non-catalytic subunit

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PRKAG3 mRNA

NCBI chr 1:74,778,062...74,788,623
Ensembl chr 1:74,778,081...74,788,380

G

protein kinase C, epsilon

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PRKCE mRNA

NCBI chr17:86,472,631...86,965,347
Ensembl chr17:86,475,213...86,965,347

G

protein kinase C, iota

increases expression

chrysene results in increased expression of PRKCI mRNA

NCBI chr 3:31,049,893...31,106,889
Ensembl chr 3:31,049,896...31,107,108

G

proline and serine rich 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PROSER2 mRNA

NCBI chr 2:6,103,304...6,135,100
Ensembl chr 2:6,102,418...6,135,022

G

PRP38 pre-mRNA processing factor 38 (yeast) domain containing B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PRPF38B mRNA

NCBI chr 3:108,810,121...108,819,055
Ensembl chr 3:108,810,121...108,819,043

G

pre-mRNA processing factor 4B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PRPF4B mRNA

NCBI chr13:35,058,803...35,090,047
Ensembl chr13:35,059,285...35,090,047

G

proline rich 7 (synaptic)

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PRR7 mRNA

NCBI chr13:55,612,080...55,620,968
Ensembl chr13:55,612,080...55,620,967

G

proline rich Gla (G-carboxyglutamic acid) 3 (transmembrane)

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PRRG3 mRNA

NCBI chr X:71,005,769...71,016,328
Ensembl chr X:71,006,230...71,016,328

G

serine protease 12 neurotrypsin (motopsin)

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PRSS12 mRNA

NCBI chr 3:123,240,562...123,300,251
Ensembl chr 3:123,240,562...123,300,246

G

serine protease 23

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PRSS23 mRNA

NCBI chr 7:89,156,988...89,176,399
Ensembl chr 7:89,156,991...89,176,395

G

proteasome (prosome, macropain) 26S subunit, non-ATPase, 3

increases expression

chrysene results in increased expression of PSMD3 mRNA

NCBI chr11:98,573,380...98,586,804
Ensembl chr11:98,573,380...98,586,805

G

proline/serine-rich coiled-coil 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PSRC1 mRNA

NCBI chr 3:108,291,120...108,295,547
Ensembl chr 3:108,291,155...108,295,547

G

polypyrimidine tract binding protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PTBP1 mRNA

NCBI chr10:79,690,502...79,700,269
Ensembl chr10:79,690,261...79,700,605

G

prothymosin alpha

increases expression
multiple interactions

chrysene results in increased expression of PTMA mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PTMA mRNA

PMID:26377693 PMID:27858113

NCBI chr 1:86,454,442...86,458,434
Ensembl chr 1:86,454,448...86,458,434

G

protein tyrosine phosphatase, non-receptor type 5

decreases expression

chrysene results in decreased expression of PTPN5 mRNA

NCBI chr 7:46,727,543...46,783,774
Ensembl chr 7:46,727,543...46,783,432

G

protein tyrosine phosphatase receptor type B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PTPRB mRNA

NCBI chr10:116,111,407...116,225,443
Ensembl chr10:116,111,428...116,225,440

G

protein tyrosine phosphatase receptor type G

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PTPRG mRNA

NCBI chr14:10,227,722...10,916,341
Ensembl chr14:10,227,722...10,916,220

G

protein tyrosine phosphatase receptor type Z, polypeptide 1

increases expression

chrysene results in increased expression of PTPRZ1 mRNA

NCBI chr 6:22,875,302...23,052,915
Ensembl chr 6:22,875,501...23,052,915

G

PWWP domain containing 4B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PWWP4B mRNA

NCBI chr X:72,180,829...72,193,071
Ensembl chr X:72,180,838...72,193,056

G

RAB11 family interacting protein 1 (class I)

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RAB11FIP1 mRNA

NCBI chr 8:27,628,801...27,664,707
Ensembl chr 8:27,628,801...27,664,674

G

RAB44, member RAS oncogene family

increases expression

chrysene results in increased expression of RAB44 mRNA

NCBI chr17:29,333,102...29,367,966
Ensembl chr17:29,333,119...29,367,954

G

Rab acceptor 1 (prenylated)

decreases expression

chrysene results in decreased expression of RABAC1 mRNA

NCBI chr 7:24,669,175...24,672,153
Ensembl chr 7:24,669,177...24,672,179

G

Rab geranylgeranyl transferase, b subunit

decreases expression

chrysene results in decreased expression of RABGGTB mRNA

NCBI chr 3:153,612,926...153,618,603
Ensembl chr 3:153,612,924...153,618,646

G

RAD51 recombinase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RAD51 mRNA

NCBI chr 2:118,943,295...118,966,554
Ensembl chr 2:118,943,274...118,977,926

G

retinoic acid induced 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RAI2 mRNA

NCBI chr X:160,500,032...160,562,490
Ensembl chr X:160,500,065...160,562,492

G

receptor (calcitonin) activity modifying protein 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RAMP3 mRNA

NCBI chr11:6,608,507...6,627,478
Ensembl chr11:6,608,521...6,627,475

G

RASD family, member 2

increases expression
multiple interactions

chrysene results in increased expression of RASD2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RASD2 mRNA

PMID:26377693 PMID:27858113

NCBI chr 8:75,940,572...75,950,741
Ensembl chr 8:75,940,572...75,950,741

G

RasGEF domain family, member 1C

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RASGEF1C mRNA

NCBI chr11:49,791,996...49,871,050
Ensembl chr11:49,792,662...49,871,821

G

RAS, guanyl releasing protein 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RASGRP3 mRNA

NCBI chr17:75,742,849...75,836,049
Ensembl chr17:75,742,891...75,836,049

G

RAS-like, family 11, member A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RASL11A mRNA

NCBI chr 5:146,781,881...146,784,536
Ensembl chr 5:146,781,881...146,784,537

G

Ras association (RalGDS/AF-6) domain family member 1

increases expression

chrysene results in increased expression of RASSF1 mRNA

NCBI chr 9:107,428,752...107,439,460
Ensembl chr 9:107,428,754...107,439,466

G

Ras association (RalGDS/AF-6) domain family (N-terminal) member 8

decreases expression

chrysene results in decreased expression of RASSF8 mRNA

NCBI chr 6:145,692,292...145,766,805
Ensembl chr 6:145,692,474...145,766,805

G

RNA binding motif protein 25

increases expression

chrysene results in increased expression of RBM25 mRNA

NCBI chr12:83,678,990...83,729,901
Ensembl chr12:83,678,010...83,729,897

G

RNA binding motif protein 39

increases expression

chrysene results in increased expression of RBM39 mRNA

NCBI chr 2:155,989,159...156,022,649
Ensembl chr 2:155,989,159...156,022,158

G

RNA binding motif protein 6

increases expression

chrysene results in increased expression of RBM6 mRNA

NCBI chr 9:107,650,758...107,751,028
Ensembl chr 9:107,650,758...107,750,436

G

retinol binding protein 1, cellular

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RBP1 mRNA

NCBI chr 9:98,305,014...98,328,604
Ensembl chr 9:98,305,014...98,328,628

G

receptor accessory protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of REEP1 mRNA

NCBI chr 6:71,684,413...71,787,694
Ensembl chr 6:71,684,545...71,787,694

G

receptor accessory protein 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of REEP2 mRNA

NCBI chr18:34,973,642...34,980,516
Ensembl chr18:34,973,642...34,980,516

G

REV1, DNA directed polymerase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of REV1 mRNA

NCBI chr 1:38,091,867...38,169,191
Ensembl chr 1:38,091,867...38,168,882

G

REX4, 3'-5' exonuclease

increases expression

chrysene results in increased expression of REXO4 mRNA

NCBI chr 2:26,843,575...26,854,398
Ensembl chr 2:26,843,575...26,854,398

G

regulator of G-protein signaling 12

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RGS12 mRNA

NCBI chr 5:35,106,273...35,196,988
Ensembl chr 5:35,106,789...35,196,988

G

regulator of G-protein signalling 7 binding protein

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RGS7BP mRNA

NCBI chr13:105,082,412...105,191,438
Ensembl chr13:105,082,412...105,191,438

G

ras homolog family member B

decreases expression
multiple interactions

chrysene results in decreased expression of RHOB mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RHOB mRNA

PMID:26377693 PMID:27858113

NCBI chr12:8,547,661...8,550,009
Ensembl chr12:8,547,661...8,550,009

G

ras homolog family member C

increases expression

chrysene results in increased expression of RHOC mRNA

NCBI chr 3:104,696,350...104,701,775
Ensembl chr 3:104,695,691...104,701,775

G

ras homolog family member T2

increases expression

chrysene results in increased expression of RHOT2 mRNA

NCBI chr17:26,057,431...26,063,499
Ensembl chr17:26,057,431...26,063,825

G

reproductive homeobox 8

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RHOX8 mRNA

NCBI chr X:36,963,657...36,979,643
Ensembl chr X:36,963,655...36,967,821

G

ripply transcriptional repressor 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RIPPLY3 mRNA

NCBI chr16:94,129,281...94,137,794
Ensembl chr16:94,129,279...94,137,794

G

RNA component of mitochondrial RNAase P

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RMRP mRNA

NCBI chr 4:43,492,785...43,493,059
Ensembl chr 4:43,492,788...43,493,058
Ensembl chr 4:43,492,788...43,493,058

G

4.5S RNA

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RN4.5S mRNA

NCBI chr 6:47,631,855...47,632,028

G

ribonuclease, RNase A family, 10 (non-active)

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RNASE10 mRNA

NCBI chr14:51,245,208...51,248,218
Ensembl chr14:51,245,208...51,248,215

G

ribonuclease H2, subunit B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RNASEH2B mRNA

NCBI chr14:62,569,517...62,610,445
Ensembl chr14:62,530,038...62,610,441

G

ring finger protein 144A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RNF144A mRNA

NCBI chr12:26,356,796...26,465,296
Ensembl chr12:26,350,963...26,465,253

G

ring finger protein 169

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RNF169 mRNA

NCBI chr 7:99,569,461...99,630,537
Ensembl chr 7:99,569,461...99,629,655

G

ring finger protein 20

increases expression

chrysene results in increased expression of RNF20 mRNA

NCBI chr 4:49,632,005...49,656,887
Ensembl chr 4:49,632,006...49,656,887

G

ring finger protein 43

increases expression

chrysene results in increased expression of RNF43 mRNA

NCBI chr11:87,553,913...87,626,365
Ensembl chr11:87,553,548...87,626,365

G

U2 small nuclear RNA 10

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RNU2-10 mRNA

NCBI chr11:101,549,064...101,549,250
Ensembl chr11:101,549,064...101,549,254

G

roundabout guidance receptor 1

decreases expression

chrysene results in decreased expression of ROBO1 mRNA

NCBI chr16:71,824,406...72,844,379
Ensembl chr16:72,105,194...72,842,983

G

Rho-associated coiled-coil containing protein kinase 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ROCK2 mRNA

NCBI chr12:16,944,808...17,038,275
Ensembl chr12:16,944,896...17,037,824

G

RAR-related orphan receptor gamma

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RORC mRNA

NCBI chr 3:94,280,106...94,305,583
Ensembl chr 3:94,280,101...94,305,583

G

RNA polymerase II associated protein 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RPAP2 mRNA

NCBI chr 5:107,745,239...107,809,719
Ensembl chr 5:107,745,239...107,809,704

G

ribosomal protein S27-like

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RPS27L mRNA

NCBI chr 9:66,851,906...66,856,804
Ensembl chr 9:66,853,368...66,856,798

G

ribosomal protein S3A3

decreases expression

chrysene results in decreased expression of RPS3A3 mRNA

NCBI chr13:108,807,114...108,807,977
Ensembl chr13:108,807,137...108,807,931

G

ribonucleotide reductase M1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RRM1 mRNA

NCBI chr 7:102,090,902...102,118,978
Ensembl chr 7:102,090,902...102,118,978

G

ribonucleotide reductase M2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RRM2 mRNA

NCBI chr12:24,758,253...24,764,145
Ensembl chr12:24,758,240...24,764,145

G

ribosomal RNA processing 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RRP1 mRNA

NCBI chr10:78,236,196...78,248,877
Ensembl chr10:78,236,218...78,248,877

G

retinoschisis (X-linked, juvenile) 1 (human)

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RS1 mRNA

NCBI chr X:159,548,815...159,584,800
Ensembl chr X:159,551,009...159,582,659

G

5.8S ribosomal RNA

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RS5-8S1 mRNA

G

arginine/serine rich protein 1

increases expression

chrysene results in increased expression of RSRP1 mRNA

NCBI chr 4:134,650,936...134,654,681
Ensembl chr 4:134,650,903...134,654,982

G

reticulon 3

decreases expression

chrysene results in decreased expression of RTN3 mRNA

NCBI chr19:7,403,260...7,460,656
Ensembl chr19:7,403,266...7,460,646

G

receptor transporter protein 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RTP3 mRNA

NCBI chr 9:110,814,003...110,818,781
Ensembl chr 9:110,814,003...110,819,651

G

receptor transporter protein 4

decreases expression

chrysene results in decreased expression of RTP4 mRNA

NCBI chr16:23,338,976...23,432,972
Ensembl chr16:23,339,041...23,432,972

G

RUN and FYVE domain-containing 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RUFY2 mRNA

NCBI chr10:62,815,947...62,852,988
Ensembl chr10:62,816,002...62,852,989

G

ryanodine receptor 1, skeletal muscle

increases expression

chrysene results in increased expression of RYR1 mRNA

NCBI chr 7:28,702,765...28,824,599
Ensembl chr 7:28,702,769...28,824,604

G

S100 calcium binding protein A14

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of S100A14 mRNA

NCBI chr 3:90,434,156...90,436,144
Ensembl chr 3:90,434,163...90,436,144

G

S100 calcium binding protein A6 (calcyclin)

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of S100A6 mRNA

NCBI chr 3:90,520,491...90,531,797
Ensembl chr 3:90,520,189...90,531,488

G

sphingosine-1-phosphate receptor 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of S1PR1 mRNA

NCBI chr 3:115,504,082...115,508,704
Ensembl chr 3:115,504,082...115,508,721

G

SAC3 domain containing 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SAC3D1 mRNA

NCBI chr19:6,166,025...6,168,689
Ensembl chr19:6,166,030...6,168,680

G

scaffold attachment factor B2

increases expression

chrysene results in increased expression of SAFB2 mRNA

NCBI chr17:56,867,971...56,891,673
Ensembl chr17:56,867,965...56,891,585

G

suprabasin

increases expression

chrysene results in increased expression of SBSN mRNA

NCBI chr 7:30,432,099...30,455,559
Ensembl chr 7:30,450,896...30,455,559

G

stearoyl-Coenzyme A desaturase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SCD1 mRNA

NCBI chr19:44,382,889...44,396,148
Ensembl chr19:44,382,894...44,396,318

G

sodium channel, voltage-gated, type III, beta

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SCN3B mRNA

NCBI chr 9:40,180,512...40,202,914
Ensembl chr 9:40,180,513...40,202,914

G

SCY1-like 1 (S. cerevisiae)

increases expression

chrysene results in increased expression of SCYL1 mRNA

NCBI chr19:5,808,450...5,821,461
Ensembl chr19:5,808,379...5,821,447

G

stromal cell derived factor 4

decreases expression
multiple interactions

chrysene results in decreased expression of SDF4 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SDF4 mRNA

PMID:26377693 PMID:27858113

NCBI chr 4:156,077,300...156,098,067
Ensembl chr 4:156,077,329...156,098,067

G

secretory blood group 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SEC1 mRNA

NCBI chr 7:45,327,110...45,343,825
Ensembl chr 7:45,327,110...45,343,826

G

SEC61 translocon subunit beta

decreases expression

chrysene results in decreased expression of SEC61B mRNA

NCBI chr 4:47,474,661...47,483,233
Ensembl chr 4:47,474,658...47,483,242

G

selenoprotein S

decreases expression

chrysene results in decreased expression of SELENOS mRNA

NCBI chr 7:65,729,397...65,739,153
Ensembl chr 7:65,729,397...65,739,153

G

selectin, lymphocyte

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SELL mRNA

NCBI chr 1:163,889,556...163,908,354
Ensembl chr 1:163,889,551...163,911,750

G

sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3C

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SEMA3C mRNA

NCBI chr 5:17,779,814...17,935,266
Ensembl chr 5:17,779,279...17,935,266

G

septin 11

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SEPTIN11 mRNA

NCBI chr 5:93,227,445...93,329,237
Ensembl chr 5:93,241,296...93,324,306

G

septin 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SEPTIN3 mRNA

NCBI chr15:82,153,003...82,178,775
Ensembl chr15:82,153,003...82,178,775

G

stress-associated endoplasmic reticulum protein family member 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SERP2 mRNA

NCBI chr14:76,770,252...76,794,518
Ensembl chr14:76,770,254...76,794,329

G

serine (or cysteine) peptidase inhibitor, clade A, member 1A

increases expression

chrysene results in increased expression of SERPINA1A mRNA

NCBI chr12:103,819,554...103,829,878
Ensembl chr12:103,819,848...103,829,821

G

serine (or cysteine) peptidase inhibitor, clade A, member 1C

increases expression

chrysene results in increased expression of SERPINA1C mRNA

NCBI chr12:103,861,185...103,871,209
Ensembl chr12:103,861,185...103,871,146

G

serine (or cysteine) peptidase inhibitor, clade A, member 1D

increases expression

chrysene results in increased expression of SERPINA1D mRNA

NCBI chr12:103,729,846...103,739,892
Ensembl chr12:103,729,853...103,739,851

G

serine (or cysteine) peptidase inhibitor, clade A, member 1E

increases expression

chrysene results in increased expression of SERPINA1E mRNA

NCBI chr12:103,913,190...103,923,156
Ensembl chr12:103,913,190...103,925,234

G

serine (or cysteine) peptidase inhibitor, clade A, member 3F

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SERPINA3F mRNA

NCBI chr12:104,180,803...104,187,388
Ensembl chr12:104,180,803...104,187,388

G

serine (or cysteine) peptidase inhibitor, clade A, member 3G

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SERPINA3G mRNA

NCBI chr12:104,202,406...104,208,198
Ensembl chr12:104,202,504...104,208,198

G

serine (or cysteine) peptidase inhibitor, clade A, member 3H

increases expression

chrysene results in increased expression of SERPINA3H mRNA

NCBI chr12:104,214,155...104,220,664
Ensembl chr12:104,216,411...104,219,928
Ensembl chr12:104,216,411...104,219,928

G

serine (or cysteine) peptidase inhibitor, clade A, member 3I

increases expression

chrysene results in increased expression of SERPINA3I mRNA

NCBI chr12:104,229,304...104,235,768
Ensembl chr12:104,229,381...104,235,631

G

serine (or cysteine) peptidase inhibitor, clade B (ovalbumin), member 10

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SERPINB10 mRNA

NCBI chr 1:107,456,724...107,488,469
Ensembl chr 1:107,456,757...107,477,001

G

serine (or cysteine) peptidase inhibitor, clade B, member 1a

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SERPINB1A mRNA

NCBI chr13:33,026,075...33,037,189
Ensembl chr13:33,026,075...33,035,168

G

serine (or cysteine) peptidase inhibitor, clade B, member 3C

increases expression

chrysene results in increased expression of SERPINB3C mRNA

NCBI chr 1:107,198,931...107,206,101
Ensembl chr 1:107,198,931...107,206,101

G

serine (or cysteine) peptidase inhibitor, clade B, member 5

increases expression

chrysene results in increased expression of SERPINB5 mRNA

NCBI chr 1:106,788,905...106,811,078
Ensembl chr 1:106,788,903...106,811,078

G

serine (or cysteine) peptidase inhibitor, clade E, member 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SERPINE1 mRNA

NCBI chr 5:137,090,358...137,101,126
Ensembl chr 5:137,090,358...137,101,122

G

SERTA domain containing 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SERTAD2 mRNA

NCBI chr11:20,493,166...20,603,023
Ensembl chr11:20,493,253...20,603,021

G

sestrin 2

decreases expression
multiple interactions

chrysene results in decreased expression of SESN2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SESN2 mRNA

PMID:26377693 PMID:27858113

NCBI chr 4:132,220,115...132,237,767
Ensembl chr 4:132,219,343...132,237,812

G

SET domain containing 1B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SETD1B mRNA

NCBI chr 5:123,280,109...123,306,693
Ensembl chr 5:123,280,256...123,306,692

G

SET domain containing 6

increases expression

chrysene results in increased expression of SETD6 mRNA

NCBI chr 8:96,442,211...96,448,135
Ensembl chr 8:96,442,509...96,445,638

G

Sfi1 homolog, spindle assembly associated (yeast)

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SFI1 mRNA

NCBI chr11:3,081,850...3,153,344
Ensembl chr11:3,081,850...3,143,463

G

SWI5 dependent recombination repair 1

increases expression

chrysene results in increased expression of SFR1 mRNA

NCBI chr19:47,720,159...47,724,027
Ensembl chr19:47,720,121...47,724,027

G

secreted frizzled-related protein 2

increases expression

chrysene results in increased expression of SFRP2 mRNA

NCBI chr 3:83,673,628...83,681,621
Ensembl chr 3:83,673,628...83,681,623

G

sideroflexin 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SFXN2 mRNA

NCBI chr19:46,561,798...46,585,340
Ensembl chr19:46,561,804...46,586,505

G

sphingomyelin synthase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SGMS1 mRNA

NCBI chr19:32,100,127...32,367,285
Ensembl chr19:32,100,127...32,367,114

G

SH3-binding domain glutamic acid-rich protein

increases expression

chrysene results in increased expression of SH3BGR mRNA

NCBI chr16:96,001,670...96,030,133
Ensembl chr16:96,001,650...96,030,135

G

SH3-domain binding protein 1

increases expression

chrysene results in increased expression of SH3BP1 mRNA

NCBI chr15:78,783,994...78,796,247
Ensembl chr15:78,783,968...78,796,251

G

SH3 domain protein D19

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SH3D19 mRNA

NCBI chr 3:85,878,112...86,037,833
Ensembl chr 3:85,878,416...86,037,833

G

SH3 and PX domains 2A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SH3PXD2A mRNA

NCBI chr19:47,248,613...47,453,053
Ensembl chr19:47,248,613...47,452,840

G

SHC (Src homology 2 domain containing) family, member 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SHC4 mRNA

NCBI chr 2:125,469,359...125,566,085
Ensembl chr 2:125,469,367...125,566,068

G

shisa family member 2

increases expression

chrysene results in increased expression of SHISA2 mRNA

NCBI chr14:59,862,730...59,869,109
Ensembl chr14:59,862,757...59,869,109

G

sialic acid binding Ig-like lectin H

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SIGLECH mRNA

NCBI chr 7:55,417,916...55,429,196
Ensembl chr 7:55,417,926...55,428,673

G

solute carrier family 19 (thiamine transporter), member 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SLC19A2 mRNA

NCBI chr 1:164,076,615...164,092,954
Ensembl chr 1:164,076,615...164,092,954

G

solute carrier family 25, member 33

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SLC25A33 mRNA

NCBI chr 4:149,828,493...149,858,746
Ensembl chr 4:149,828,493...149,858,734

G

solute carrier family 26, member 10

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SLC26A10 mRNA

NCBI chr10:127,007,262...127,016,690
Ensembl chr10:127,007,262...127,016,514

G

solute carrier family 26, member 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SLC26A4 mRNA

NCBI chr12:31,569,813...31,610,054
Ensembl chr12:31,569,826...31,609,968

G

solute carrier family 2 (facilitated glucose transporter), member 6

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SLC2A6 mRNA

NCBI chr 2:26,911,375...26,918,011
Ensembl chr 2:26,911,375...26,918,010

G

solute carrier family 2 (facilitated glucose transporter), member 9

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SLC2A9 mRNA

NCBI chr 5:38,506,616...38,660,488
Ensembl chr 5:38,506,616...38,660,486

G

solute carrier family 30 (zinc transporter), member 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SLC30A1 mRNA

NCBI chr 1:191,638,810...191,645,359
Ensembl chr 1:191,638,879...191,645,359

G

solute carrier family 35, member G2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SLC35G2 mRNA

NCBI chr 9:100,431,178...100,453,138
Ensembl chr 9:100,434,241...100,453,143

G

solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2

increases expression

chrysene results in increased expression of SLC3A2 mRNA

NCBI chr19:8,684,931...8,700,733
Ensembl chr19:8,684,246...8,700,733

G

solute carrier family 45, member 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SLC45A4 mRNA

NCBI chr15:73,449,267...73,517,606
Ensembl chr15:73,449,273...73,517,611

G

solute carrier family 46, member 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SLC46A3 mRNA

NCBI chr 5:147,812,707...147,831,670
Ensembl chr 5:147,815,247...147,831,625

G

solute carrier family 5 (sodium/glucose cotransporter), member 12

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SLC5A12 mRNA

NCBI chr 2:110,427,644...110,479,690
Ensembl chr 2:110,427,643...110,478,124

G

solute carrier family 5 (inositol transporters), member 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SLC5A3 mRNA

NCBI chr16:91,855,210...91,884,361
Ensembl chr16:91,855,210...91,884,361

G

solute carrier family 66 member 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SLC66A3 mRNA

NCBI chr12:17,038,649...17,050,385
Ensembl chr12:17,038,649...17,050,409

G

solute carrier family 7 (cationic amino acid transporter, y+ system), member 5

increases expression

chrysene results in increased expression of SLC7A5 mRNA

NCBI chr 8:122,607,885...122,634,425
Ensembl chr 8:122,607,889...122,634,433

G

solute carrier family 8 (sodium/calcium exchanger), member 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SLC8A1 mRNA

NCBI chr17:81,680,534...82,045,816
Ensembl chr17:81,680,534...82,045,806

G

sarcolemma associated protein

increases expression

chrysene results in increased expression of SLMAP mRNA

NCBI chr14:26,134,323...26,256,103
Ensembl chr14:26,134,323...26,256,086

G

SWI/SNF related, matrix associated, actin depenent ragulator of chromatin, subfamily a, member 5, pseudogene

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SMARCA5-PS mRNA

NCBI chr 4:145,190,780...145,194,531
Ensembl chr 4:145,190,868...145,193,990

G

structural maintenance of chromosomes 1A

increases expression

chrysene results in increased expression of SMC1A mRNA

NCBI chr X:150,799,386...150,844,969
Ensembl chr X:150,799,424...150,845,690

G

SPARC related modular calcium binding 2

increases expression

chrysene results in increased expression of SMOC2 mRNA

NCBI chr17:14,499,768...14,625,052
Ensembl chr17:14,499,768...14,625,052

G

sphingomyelin phosphodiesterase 2, neutral

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SMPD2 mRNA

NCBI chr10:41,363,168...41,366,410
Ensembl chr10:41,361,638...41,366,365

G

sphingomyelin phosphodiesterase 3, neutral

increases expression

chrysene results in increased expression of SMPD3 mRNA

NCBI chr 8:106,979,180...107,064,597
Ensembl chr 8:106,979,180...107,064,620

G

SMT3 suppressor of mif two 3 homolog 2, pseudogene 2 (S. cerevisiae)

decreases expression

chrysene results in decreased expression of SMT3H2-PS2 mRNA

NCBI chr 7:126,997,057...126,998,195
Ensembl chr 7:126,997,150...126,997,437

G

smoothelin-like 1

increases expression

chrysene results in increased expression of SMTNL1 mRNA

NCBI chr 2:84,641,494...84,657,173
Ensembl chr 2:84,641,520...84,652,996

G

snail family zinc finger 2

increases expression

chrysene results in increased expression of SNAI2 mRNA

NCBI chr16:14,523,716...14,527,259
Ensembl chr16:14,523,716...14,527,249

G

synaptosomal-associated protein 23

decreases expression
multiple interactions

chrysene results in decreased expression of SNAP23 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SNAP23 mRNA

PMID:26377693 PMID:27858113

NCBI chr 2:120,398,137...120,436,829
Ensembl chr 2:120,398,152...120,431,736

G

synaptosomal-associated protein, 47

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SNAP47 mRNA

NCBI chr11:59,297,967...59,340,868
Ensembl chr11:59,297,960...59,342,012

G

small nucleolar RNA, C/D box 123

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SNORD123 mRNA

NCBI chr15:32,241,991...32,242,078
Ensembl chr15:32,241,999...32,242,069

G

small nuclear ribonucleoprotein 70 (U1)

increases expression

chrysene results in increased expression of SNRNP70 mRNA

NCBI chr 7:45,025,878...45,045,177
Ensembl chr 7:45,025,877...45,045,166

G

syntrophin, basic 1

decreases expression
multiple interactions

chrysene results in decreased expression of SNTB1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SNTB1 mRNA

PMID:26377693 PMID:27858113

NCBI chr15:55,499,784...55,770,707
Ensembl chr15:55,499,784...55,770,345

G

sorbin and SH3 domain containing 1

increases expression

chrysene results in increased expression of SORBS1 mRNA

NCBI chr19:40,280,484...40,502,399
Ensembl chr19:40,283,197...40,502,223

G

sorbitol dehydrogenase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SORD mRNA

NCBI chr 2:122,065,320...122,095,818
Ensembl chr 2:122,065,230...122,095,821

G

SRY (sex determining region Y)-box 17

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SOX17 mRNA

NCBI chr 1:4,561,154...4,567,624
Ensembl chr 1:4,561,154...4,567,577

G

SRY (sex determining region Y)-box 2

increases expression

chrysene results in increased expression of SOX2 mRNA

NCBI chr 3:34,704,144...34,706,610
Ensembl chr 3:34,704,554...34,706,610

G

SRY (sex determining region Y)-box 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SOX4 mRNA

NCBI chr13:29,132,902...29,137,682
Ensembl chr13:29,132,902...29,137,696

G

SPARC-like 1

increases expression

chrysene results in increased expression of SPARCL1 mRNA

NCBI chr 5:104,226,974...104,261,954
Ensembl chr 5:104,226,977...104,261,599

G

SPC25, NDC80 kinetochore complex component, homolog (S. cerevisiae)

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SPC25 mRNA

NCBI chr 2:69,009,753...69,036,583
Ensembl chr 2:69,024,239...69,036,538

G

signal peptidase complex subunit 2 homolog (S. cerevisiae)

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SPCS2 mRNA

NCBI chr 7:99,486,775...99,512,576
Ensembl chr 7:99,486,776...99,512,669

G

Spi-B transcription factor (Spi-1/PU.1 related)

increases expression

chrysene results in increased expression of SPIB mRNA

NCBI chr 7:44,175,419...44,181,511
Ensembl chr 7:44,175,417...44,181,495

G

spindlin 1

decreases expression
multiple interactions

chrysene results in decreased expression of SPIN1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SPIN1 mRNA

PMID:26377693 PMID:27858113

NCBI chr13:51,254,523...51,306,588
Ensembl chr13:51,254,916...51,306,582

G

serine peptidase inhibitor, Kazal type 1

increases expression

chrysene results in increased expression of SPINK1 mRNA

NCBI chr18:43,861,134...43,870,302
Ensembl chr18:43,861,147...43,870,622

G

spondin 2, extracellular matrix protein

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SPON2 mRNA

NCBI chr 5:33,370,862...33,375,596
Ensembl chr 5:33,355,528...33,375,799

G

secreted phosphoprotein 1

decreases expression

chrysene results in decreased expression of SPP1 mRNA

NCBI chr 5:104,582,977...104,588,919
Ensembl chr 5:104,582,984...104,588,916

G

spectrin beta, non-erythrocytic 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SPTBN1 mRNA

NCBI chr11:30,049,395...30,218,384
Ensembl chr11:30,049,395...30,218,175

G

SRC kinase signaling inhibitor 1

increases expression

chrysene results in increased expression of SRCIN1 mRNA

NCBI chr11:97,400,166...97,466,059
Ensembl chr11:97,400,166...97,467,012

G

serglycin

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SRGN mRNA

NCBI chr10:62,329,612...62,363,224
Ensembl chr10:62,329,612...62,363,230

G

signal recognition particle 9

decreases expression

chrysene results in decreased expression of SRP9 mRNA

NCBI chr 1:181,952,302...181,959,980
Ensembl chr 1:181,952,302...181,959,972

G

serine/arginine-rich protein specific kinase 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SRPK3 mRNA

NCBI chr X:72,818,011...72,822,531
Ensembl chr X:72,818,011...72,822,531

G

serine/arginine repetitive matrix 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SRRM2 mRNA

NCBI chr17:24,009,501...24,043,715
Ensembl chr17:24,009,506...24,043,715

G

serine and arginine-rich splicing factor 5

increases expression

chrysene results in increased expression of SRSF5 mRNA

NCBI chr12:80,992,308...80,997,277
Ensembl chr12:80,992,278...80,997,281

G

small RNA binding exonuclease protection factor La

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SSB mRNA

NCBI chr 2:69,691,963...69,702,185
Ensembl chr 2:69,691,906...69,702,190

G

slingshot protein phosphatase 3

increases expression

chrysene results in increased expression of SSH3 mRNA

NCBI chr19:4,311,696...4,319,261
Ensembl chr19:4,311,696...4,319,208

G

sarcospan

increases expression
multiple interactions

chrysene results in increased expression of SSPN mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SSPN mRNA

PMID:26377693 PMID:27858113

NCBI chr 6:145,860,423...145,910,951
Ensembl chr 6:145,877,367...145,910,949

G

signal sequence receptor, beta

decreases expression

chrysene results in decreased expression of SSR2 mRNA

NCBI chr 3:88,486,915...88,495,727
Ensembl chr 3:88,483,183...88,495,726

G

signal sequence receptor, gamma

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SSR3 mRNA

NCBI chr 3:65,287,078...65,299,974
Ensembl chr 3:65,287,076...65,300,044

G

ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-sialyltransferase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ST6GALNAC1 mRNA

NCBI chr11:116,655,851...116,666,333
Ensembl chr11:116,655,851...116,666,333

G

ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ST8SIA4 mRNA

NCBI chr 1:95,515,407...95,595,473
Ensembl chr 1:95,515,407...95,595,296

G

staufen double-stranded RNA binding protein 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of STAU2 mRNA

NCBI chr 1:16,299,027...16,591,228
Ensembl chr 1:16,298,898...16,590,336

G

starch binding domain 1

increases expression

chrysene results in increased expression of STBD1 mRNA

NCBI chr 5:92,750,910...92,754,438
Ensembl chr 5:92,750,900...92,754,438

G

stefin A1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of STFA1 mRNA

NCBI chr16:36,097,510...36,105,733
Ensembl chr16:36,097,313...36,105,735

G

sulfatase 1

increases expression

chrysene results in increased expression of SULF1 mRNA

NCBI chr 1:12,762,421...12,946,090
Ensembl chr 1:12,762,501...12,931,416

G

small ubiquitin-like modifier 2

decreases expression

chrysene results in decreased expression of SUMO2 mRNA

NCBI chr11:115,413,935...115,427,056
Ensembl chr11:115,413,928...115,427,102

G

spectrin repeat containing, nuclear envelope 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SYNE2 mRNA

NCBI chr12:75,865,092...76,157,702
Ensembl chr12:75,864,908...76,157,700

G

SYS1 Golgi-localized integral membrane protein homolog (S. cerevisiae)

decreases expression

chrysene results in decreased expression of SYS1 mRNA

NCBI chr 2:164,297,736...164,322,141
Ensembl chr 2:164,298,884...164,321,558

G

synaptotagmin X

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SYT10 mRNA

NCBI chr15:89,657,221...89,726,181
Ensembl chr15:89,666,596...89,726,063

G

synaptotagmin XV

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SYT15 mRNA

NCBI chr14:33,941,915...33,952,378
Ensembl chr14:33,941,552...33,952,377

G

TGF-beta activated kinase 1/MAP3K7 binding protein 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TAB2 mRNA

NCBI chr10:7,781,412...7,832,039
Ensembl chr10:7,781,417...7,831,994

G

transforming, acidic coiled-coil containing protein 2

increases expression

chrysene results in increased expression of TACC2 mRNA

NCBI chr 7:130,154,735...130,369,435
Ensembl chr 7:130,179,168...130,366,515

G

transcriptional adaptor 2A

increases expression

chrysene results in increased expression of TADA2A mRNA

NCBI chr11:83,969,746...84,020,466
Ensembl chr11:83,969,746...84,020,426

G

TATA-box binding protein associated factor 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TAF1 mRNA

NCBI chr X:100,576,335...100,644,635
Ensembl chr X:100,576,279...100,644,640

G

transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TAP1 mRNA

NCBI chr17:34,406,530...34,416,199
Ensembl chr17:34,406,527...34,416,199

G

TAR DNA binding protein

increases expression

chrysene results in increased expression of TARDBP mRNA

NCBI chr 4:148,696,839...148,711,672
Ensembl chr 4:148,696,839...148,711,476

G

T-box 21

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TBX21 mRNA

NCBI chr11:96,988,833...97,006,157
Ensembl chr11:96,988,897...97,006,157

G

transcription elongation factor A (SII), 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TCEA3 mRNA

NCBI chr 4:135,975,253...136,002,214
Ensembl chr 4:135,975,040...136,002,209

G

transcription factor 19

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TCF19 mRNA

NCBI chr17:35,823,627...35,827,730
Ensembl chr17:35,823,631...35,827,721

G

transcription factor 7 like 2, T cell specific, HMG box

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TCF7L2 mRNA

NCBI chr19:55,730,227...55,922,091
Ensembl chr19:55,730,252...55,922,086

G

treacle ribosome biogenesis factor 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TCOF1 mRNA

NCBI chr18:60,946,827...60,982,055
Ensembl chr18:60,946,827...60,982,043

G

tudor domain containing 3

increases expression

chrysene results in increased expression of TDRD3 mRNA

NCBI chr14:87,647,598...87,782,944
Ensembl chr14:87,654,075...87,782,940

G

testis development related protein

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TDRP mRNA

NCBI chr 8:14,002,008...14,025,484
Ensembl chr 8:14,002,008...14,025,032

G

tec protein tyrosine kinase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TEC mRNA

NCBI chr 5:72,913,061...73,025,997
Ensembl chr 5:72,913,059...73,025,826

G

tectonin beta-propeller repeat containing 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TECPR1 mRNA

NCBI chr 5:144,131,260...144,160,433
Ensembl chr 5:144,131,260...144,160,433

G

transmembrane epididymal family member 3

increases expression

chrysene results in increased expression of TEDDM3 mRNA

NCBI chr16:20,971,409...20,972,694
Ensembl chr16:20,971,405...20,972,750

G

thyrotroph embryonic factor

increases expression
multiple interactions

chrysene results in increased expression of TEF mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TEF mRNA

PMID:26377693 PMID:27858113

NCBI chr15:81,686,874...81,711,064
Ensembl chr15:81,686,622...81,711,064

G

teneurin transmembrane protein 2

increases expression

chrysene results in increased expression of TENM2 mRNA

NCBI chr11:35,897,483...37,881,486
Ensembl chr11:35,897,483...37,126,791

G

teneurin transmembrane protein 4

increases expression

chrysene results in increased expression of TENM4 mRNA

NCBI chr 7:95,550,262...96,560,300
Ensembl chr 7:95,820,453...96,560,300

G

TEPSIN, adaptor related protein complex 4 accessory protein

increases expression

chrysene results in increased expression of TEPSIN mRNA

NCBI chr11:119,981,348...119,989,675
Ensembl chr11:119,981,357...119,989,557

G

testis expressed gene 11

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TEX11 mRNA

NCBI chr X:99,882,254...100,103,245
Ensembl chr X:99,882,254...100,103,273

G

transcription factor CP2-like 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TFCP2L1 mRNA

NCBI chr 1:118,555,646...118,612,898
Ensembl chr 1:118,555,675...118,612,898

G

thrombospondin 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of THBS1 mRNA

NCBI chr 2:117,942,357...117,957,614
Ensembl chr 2:117,942,357...117,957,614

G

thyroid hormone receptor associated protein 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of THRAP3 mRNA

NCBI chr 4:126,057,875...126,096,548
Ensembl chr 4:126,057,875...126,096,553

G

thrombospondin, type I, domain containing 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of THSD4 mRNA

NCBI chr 9:59,874,214...60,429,394
Ensembl chr 9:59,874,214...60,429,329

G

thrombospondin, type I, domain containing 7A

decreases expression
multiple interactions

chrysene results in decreased expression of THSD7A mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of THSD7A mRNA

PMID:26377693 PMID:27858113

NCBI chr 6:12,311,607...12,749,252
Ensembl chr 6:12,311,609...12,749,409

G

thymocyte nuclear protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of THYN1 mRNA

NCBI chr 9:26,910,950...26,918,632
Ensembl chr 9:26,911,006...26,918,632

G

tissue inhibitor of metalloproteinase 1

increases expression

chrysene results in increased expression of TIMP1 mRNA

NCBI chr X:20,736,524...20,740,972
Ensembl chr X:20,736,405...20,740,974

G

TLC domain containing 3B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TLCD3B mRNA

NCBI chr 7:126,413,213...126,429,391
Ensembl chr 7:126,396,840...126,429,391

G

talin 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TLN1 mRNA

NCBI chr 4:43,531,513...43,562,583
Ensembl chr 4:43,531,519...43,562,691

G

TM2 domain containing 2

decreases expression

chrysene results in decreased expression of TM2D2 mRNA

NCBI chr 8:25,507,227...25,513,276
Ensembl chr 8:25,507,227...25,513,276

G

transmembrane p24 trafficking protein 9

decreases expression

chrysene results in decreased expression of TMED9 mRNA

NCBI chr13:55,740,948...55,745,510
Ensembl chr13:55,721,545...55,745,510

G

transmembrane protein with EGF-like and two follistatin-like domains 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TMEFF2 mRNA

NCBI chr 1:50,951,946...51,226,429
Ensembl chr 1:50,939,806...51,226,429

G

transmembrane protein 171

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TMEM171 mRNA

NCBI chr13:98,822,744...98,832,142
Ensembl chr13:98,822,743...98,831,342

G

transmembrane protein 219

decreases expression

chrysene results in decreased expression of TMEM219 mRNA

NCBI chr 7:126,485,391...126,527,993
Ensembl chr 7:126,485,343...126,522,089

G

transmembrane protein 242

decreases expression

chrysene results in decreased expression of TMEM242 mRNA

NCBI chr17:5,461,139...5,490,535
Ensembl chr17:5,461,145...5,490,534

G

transmembrane protein 245

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TMEM245 mRNA

NCBI chr 4:56,866,923...56,947,456
Ensembl chr 4:56,866,923...56,947,437

G

transmembrane protein 258

decreases expression

chrysene results in decreased expression of TMEM258 mRNA

NCBI chr19:10,181,566...10,185,188
Ensembl chr19:10,181,378...10,185,188

G

transmembrane protein 37

decreases expression

chrysene results in decreased expression of TMEM37 mRNA

NCBI chr 1:119,995,106...120,001,799
Ensembl chr 1:119,995,107...120,001,804

G

transmembrane protein 42

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TMEM42 mRNA

NCBI chr 9:122,850,072...122,852,556
Ensembl chr 9:122,850,391...122,852,770

G

transmembrane protein 91

increases expression

chrysene results in increased expression of TMEM91 mRNA

NCBI chr 7:25,368,564...25,379,011
Ensembl chr 7:25,368,564...25,374,591

G

tenascin C

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TNC mRNA

NCBI chr 4:63,878,022...63,965,554
Ensembl chr 4:63,878,022...63,965,252

G

tumor necrosis factor

increases expression

chrysene results in increased expression of TNF mRNA

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

G

tumor necrosis factor (ligand) superfamily, member 10

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TNFSF10 mRNA

NCBI chr 3:27,371,226...27,393,814
Ensembl chr 3:27,371,177...27,396,576

G

TNFAIP3 interacting protein 1

increases expression

chrysene results in increased expression of TNIP1 mRNA

NCBI chr11:54,801,613...54,853,766
Ensembl chr11:54,801,611...54,853,743

G

troponin C2, fast

increases expression

chrysene results in increased expression of TNNC2 mRNA

NCBI chr 2:164,619,081...164,621,654
Ensembl chr 2:164,619,081...164,621,887

G

troponin T3, skeletal, fast

increases expression

chrysene results in increased expression of TNNT3 mRNA

NCBI chr 7:142,052,530...142,069,746
Ensembl chr 7:142,052,573...142,069,746

G

transportin 3

increases expression

chrysene results in increased expression of TNPO3 mRNA

NCBI chr 6:29,540,826...29,609,918
Ensembl chr 6:29,540,826...29,609,886

G

tenascin XB

increases expression

chrysene results in increased expression of TNXB mRNA

NCBI chr17:34,879,427...34,938,789
Ensembl chr17:34,879,431...34,938,789

G

TOX high mobility group box family member 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TOX4 mRNA

NCBI chr14:52,516,603...52,532,966
Ensembl chr14:52,516,603...52,533,858

G

thiamine pyrophosphokinase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TPK1 mRNA

NCBI chr 6:43,316,510...43,644,726
Ensembl chr 6:43,321,935...43,643,212

G

tryptase beta 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TPSB2 mRNA

NCBI chr17:25,585,282...25,587,070
Ensembl chr17:25,585,170...25,588,079

G

TRAF3 interacting protein 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TRAF3IP3 mRNA

NCBI chr 1:192,857,812...192,883,854
Ensembl chr 1:192,857,761...192,884,011

G

tribbles pseudokinase 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TRIB2 mRNA

NCBI chr12:15,841,726...15,866,963
Ensembl chr12:15,841,728...15,866,923

G

tripartite motif-containing 35

decreases expression
multiple interactions

chrysene results in decreased expression of TRIM35 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TRIM35 mRNA

PMID:26377693 PMID:27858113

NCBI chr14:66,534,474...66,548,873
Ensembl chr14:66,534,480...66,548,873

G

transformation related protein 53

multiple interactions
increases expression

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TRP53 mRNA; chrysene promotes the reaction [Benzo(a)pyrene results in increased expression of TRP53 protein]
chrysene results in increased expression of TRP53 protein

PMID:22120587 PMID:27858113

NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699

G

transformation related protein 53 inducible nuclear protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TRP53INP1 mRNA

NCBI chr 4:11,156,441...11,174,379
Ensembl chr 4:11,156,431...11,174,379

G

transient receptor potential cation channel, subfamily V, member 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TRPV4 mRNA

NCBI chr 5:114,760,213...114,796,497
Ensembl chr 5:114,760,213...114,796,482

G

TruB pseudouridine (psi) synthase family member 2

increases expression

chrysene results in increased expression of TRUB2 mRNA

NCBI chr 2:29,651,235...29,677,697
Ensembl chr 2:29,651,236...29,678,514

G

TSC22 domain family, member 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TSC22D1 mRNA

NCBI chr14:76,652,401...76,745,205
Ensembl chr14:76,652,401...76,745,205

G

tetraspanin 17

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TSPAN17 mRNA

NCBI chr13:54,936,915...54,944,588
Ensembl chr13:54,937,190...54,944,589

G

tetraspanin 18

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TSPAN18 mRNA

NCBI chr 2:93,032,105...93,164,898
Ensembl chr 2:93,032,105...93,164,850

G

tetraspanin 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TSPAN4 mRNA

NCBI chr 7:141,055,194...141,073,340
Ensembl chr 7:141,055,153...141,073,340

G

tetratricopeptide repeat domain 7

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TTC7 mRNA

NCBI chr17:87,590,328...87,689,197
Ensembl chr17:87,590,314...87,689,197

G

tubulin tyrosine ligase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TTL mRNA

NCBI chr 2:128,907,867...128,938,203
Ensembl chr 2:128,907,862...128,938,203

G

tubulin tyrosine ligase-like family, member 7

increases expression

chrysene results in increased expression of TTLL7 mRNA

NCBI chr 3:146,557,312...146,690,156
Ensembl chr 3:146,558,122...146,689,764

G

taurine upregulated gene 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TUG1 mRNA

NCBI chr11:3,589,313...3,599,021
Ensembl chr11:3,589,785...3,599,673

G

TUB like protein 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TULP4 mRNA

NCBI chr17:6,156,528...6,290,912
Ensembl chr17:6,156,712...6,301,403

G

tumor suppressor candidate 3

decreases expression

chrysene results in decreased expression of TUSC3 mRNA

NCBI chr 8:39,472,505...39,620,091
Ensembl chr 8:39,472,999...39,619,367

G

taxilin alpha

decreases expression
multiple interactions

chrysene results in decreased expression of TXLNA mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TXLNA mRNA

PMID:26377693 PMID:27858113

NCBI chr 4:129,519,870...129,534,867
Ensembl chr 4:129,519,871...129,534,858

G

uveal autoantigen with coiled-coil domains and ankyrin repeats

increases expression

chrysene results in increased expression of UACA mRNA

NCBI chr 9:60,700,488...60,787,713
Ensembl chr 9:60,701,824...60,787,652

G

ubiquitin-conjugating enzyme E2B

decreases expression

chrysene results in decreased expression of UBE2B mRNA

NCBI chr11:51,875,965...51,894,972
Ensembl chr11:51,876,324...51,891,589

G

ubiquitin protein ligase E3 component n-recognin 5

increases expression

chrysene results in increased expression of UBR5 mRNA

NCBI chr15:37,966,421...38,084,103
Ensembl chr15:37,967,572...38,079,098

G

uncoupling protein 1 (mitochondrial, proton carrier)

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of UCP1 mRNA

NCBI chr 8:84,016,977...84,025,085
Ensembl chr 8:84,016,981...84,025,081

G

UDP glucuronosyltransferase 1 family, polypeptide A6B

increases expression

chrysene results in increased expression of UGT1A6 mRNA

NCBI chr 1:88,030,979...88,146,720
Ensembl chr 1:88,030,974...88,146,725

G

unc-45 myosin chaperone A

increases expression

chrysene results in increased expression of UNC45A mRNA

NCBI chr 7:79,975,040...79,990,748
Ensembl chr 7:79,975,040...79,997,741

G

uroplakin 1A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of UPK1A mRNA

NCBI chr 7:30,302,517...30,312,159
Ensembl chr 7:30,302,517...30,312,272

G

uroplakin 3A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of UPK3A mRNA

NCBI chr15:84,901,342...84,906,761
Ensembl chr15:84,901,342...84,906,748

G

ubiquinol-cytochrome c reductase, complex III subunit VII

decreases expression

chrysene results in decreased expression of UQCRQ mRNA

NCBI chr11:53,318,749...53,321,658
Ensembl chr11:53,318,749...53,321,658

G

ubiquitin specific peptidase 2

increases expression
multiple interactions

chrysene results in increased expression of USP2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of USP2 mRNA

PMID:26377693 PMID:27858113

NCBI chr 9:43,978,318...44,006,924
Ensembl chr 9:43,978,318...44,006,924

G

UTP14A small subunit processome component

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of UTP14A mRNA

NCBI chr X:47,345,811...47,371,326
Ensembl chr X:47,345,739...47,371,330

G

utrophin

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of UTRN mRNA

NCBI chr10:12,257,931...12,745,632
Ensembl chr10:12,257,932...12,745,109

G

vasohibin 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of VASH1 mRNA

NCBI chr12:86,725,474...86,742,462
Ensembl chr12:86,725,474...86,738,865

G

vascular cell adhesion molecule 1

decreases expression

chrysene results in decreased expression of VCAM1 mRNA

NCBI chr 3:115,903,669...115,923,337
Ensembl chr 3:115,903,598...115,923,337

G

VSP16 CORVET/HOPS core subunit

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of VPS16 mRNA

NCBI chr 2:130,265,744...130,286,189
Ensembl chr 2:130,266,259...130,286,189

G

VPS39 HOPS complex subunit

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of VPS39 mRNA

NCBI chr 2:120,146,942...120,183,618
Ensembl chr 2:120,146,942...120,183,618

G

vaccinia related kinase 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of VRK2 mRNA

NCBI chr11:26,421,398...26,544,006
Ensembl chr11:26,421,322...26,543,999

G

V-set immunoregulatory receptor

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of VSIR mRNA

NCBI chr10:60,182,630...60,266,073
Ensembl chr10:60,182,630...60,208,463

G

WASP like actin nucleation promoting factor

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of WASL mRNA

NCBI chr 6:24,613,809...24,665,185
Ensembl chr 6:24,613,804...24,665,008

G

WEE 1 homolog 1 (S. pombe)

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of WEE1 mRNA

NCBI chr 7:109,721,266...109,742,506
Ensembl chr 7:109,721,253...109,742,493

G

WAP four-disulfide core domain 12

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of WFDC12 mRNA

NCBI chr 2:164,031,151...164,032,528
Ensembl chr 2:164,031,151...164,032,528

G

WNK lysine deficient protein kinase 4

increases expression

chrysene results in increased expression of WNK4 mRNA

NCBI chr11:101,151,363...101,168,235
Ensembl chr11:101,151,393...101,168,235

G

WSC domain containing 2

increases expression

chrysene results in increased expression of WSCD2 mRNA

NCBI chr 5:113,636,976...113,727,786
Ensembl chr 5:113,638,199...113,727,786

G

WT1 transcription factor

increases expression

chrysene results in increased expression of WT1 mRNA

NCBI chr 2:104,956,874...105,003,959
Ensembl chr 2:104,956,874...105,003,961

G

X-box binding protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of XBP1 mRNA

NCBI chr11:5,470,641...5,475,993
Ensembl chr11:5,470,659...5,475,893

G

X-prolyl aminopeptidase (aminopeptidase P) 2, membrane-bound

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of XPNPEP2 mRNA

NCBI chr X:47,195,790...47,225,859
Ensembl chr X:47,197,602...47,225,858

G

yes-associated protein 1

increases expression

chrysene results in increased expression of YAP1 mRNA

NCBI chr 9:7,932,000...8,004,890
Ensembl chr 9:7,932,000...8,004,597

G

Y box protein 1

increases expression

chrysene results in increased expression of YBX1 mRNA

NCBI chr 4:119,134,524...119,153,462
Ensembl chr 4:119,135,178...119,151,801

G

yippee like 5

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of YPEL5 mRNA

NCBI chr17:73,143,623...73,157,439
Ensembl chr17:73,143,448...73,158,190

G

YTH domain containing 1

increases expression

chrysene results in increased expression of YTHDC1 mRNA

NCBI chr 5:86,951,349...86,984,518
Ensembl chr 5:86,952,080...86,984,518

G

tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of YWHAZ mRNA

NCBI chr15:36,770,505...36,803,228
Ensembl chr15:36,771,014...36,797,173

G

zinc finger CCCH type containing 7 A

increases expression

chrysene results in increased expression of ZC3H7A mRNA

NCBI chr16:10,954,458...10,994,257
Ensembl chr16:10,954,456...10,994,257

G

zinc finger, CCHC domain containing 7

increases expression

chrysene results in increased expression of ZCCHC7 mRNA

NCBI chr 4:44,756,556...44,932,215
Ensembl chr 4:44,755,877...44,932,215

G

zinc finger, DHHC-type containing 22

decreases expression

chrysene results in decreased expression of ZDHHC22 mRNA

NCBI chr12:87,027,537...87,037,604
Ensembl chr12:87,027,537...87,037,204

G

zinc finger protein 185

increases expression

chrysene results in increased expression of ZFP185 mRNA

NCBI chr X:72,030,860...72,075,149
Ensembl chr X:72,030,945...72,075,149

G

zinc finger protein 280D

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ZFP280D mRNA

NCBI chr 9:72,181,900...72,271,061
Ensembl chr 9:72,182,142...72,271,059

G

zinc finger protein 33B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ZFP33B mRNA

NCBI chr 5:104,718,441...104,734,141
Ensembl chr 5:104,719,508...104,732,487

G

zinc finger protein 346

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ZFP346 mRNA

NCBI chr13:55,253,079...55,282,884
Ensembl chr13:55,253,124...55,282,638

G

zinc finger protein 365

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ZFP365 mRNA

NCBI chr10:67,721,935...67,748,492
Ensembl chr10:67,721,933...67,748,492

G

zinc finger protein 367

decreases expression
multiple interactions

chrysene results in decreased expression of ZFP367 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ZFP367 mRNA

PMID:26377693 PMID:27858113

NCBI chr13:64,280,836...64,301,013
Ensembl chr13:64,280,832...64,301,016

G

zinc finger protein 423

increases expression

chrysene results in increased expression of ZFP423 mRNA

NCBI chr 8:88,388,438...88,688,665
Ensembl chr 8:88,388,438...88,686,223

G

zinc finger protein 62

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ZFP62 mRNA

NCBI chr11:49,093,556...49,109,643
Ensembl chr11:49,094,119...49,109,643

G

zinc finger protein 628

decreases expression
multiple interactions

chrysene results in decreased expression of ZFP628 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ZFP628 mRNA

PMID:26377693 PMID:27858113

NCBI chr 7:4,918,221...4,925,001
Ensembl chr 7:4,918,216...4,925,001

G

zinc finger protein 664

decreases expression

chrysene results in decreased expression of ZFP664 mRNA

NCBI chr 5:124,939,758...124,965,694
Ensembl chr 5:124,939,755...124,979,757

G

zinc finger protein 710

increases expression

chrysene results in increased expression of ZFP710 mRNA

NCBI chr 7:79,674,581...79,742,498
Ensembl chr 7:79,674,562...79,743,921

G

zinc finger matrin type 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ZMAT3 mRNA

NCBI chr 3:32,388,941...32,419,814
Ensembl chr 3:32,388,941...32,420,163

G

zinc finger, MYND-type containing 15

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ZMYND15 mRNA

NCBI chr11:70,350,259...70,357,028
Ensembl chr11:70,350,259...70,357,028

G

zinc finger, MYND-type containing 8

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ZMYND8 mRNA

NCBI chr 2:165,626,072...165,740,896
Ensembl chr 2:165,626,072...165,740,936

chrysen-6-ol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

progesterone receptor

multiple interactions

6-hydroxychrysene inhibits the reaction [Progesterone binds to PGR protein]; [Progesterone co-treated with 6-hydroxychrysene] results in decreased expression of PGR mRNA

NCBI chr 9:8,890,017...8,968,612
Ensembl chr 9:8,899,834...8,968,612

G

UDP glucuronosyltransferase 1 family, polypeptide A1

increases glucuronidation
multiple interactions

UGT1A1 protein results in increased glucuronidation of 6-hydroxychrysene
[Methylcholanthrene results in increased expression of UGT1A1 protein] which results in increased glucuronidation of 6-hydroxychrysene

NCBI chr 1:88,139,681...88,147,724
Ensembl chr 1:88,139,681...88,146,719

G

UDP glucuronosyltransferase 1 family, polypeptide A6B

increases glucuronidation

UGT1A6 protein results in increased glucuronidation of 6-hydroxychrysene

NCBI chr 1:88,030,979...88,146,720
Ensembl chr 1:88,030,974...88,146,725

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	22210
role	22195
biological role	22194
aetiopathogenetic role	21293
carcinogenic agent	19710
polycyclic arene	17722
ortho-fused polycyclic arene	10042
chrysene	944
hydroxychrysene +	3
Path 2
Term	Annotations
CHEBI ontology	22210
subatomic particle	22202
composite particle	22202
hadron	22202
baryon	22202
nucleon	22202
atomic nucleus	22202
atom	22202
main group element atom	22136
main group molecular entity	22136
s-block molecular entity	21732
hydrogen molecular entity	21649
hydrides	20781
organic hydride	20331
organic fundamental parent	20331
hydrocarbon	19910
cyclic hydrocarbon	17952
arene	17931
polycyclic arene	17722
ortho-fused polycyclic arene	10042
chrysene	944
hydroxychrysene +	3

paths to the root